```
=> file biosis caba caplus embase japio lifesci medline scisearch
=> e carlsson jorgen/au
E1          56     CARLSSON JORG/AU
E2           9     CARLSSON JORG DR/AU
E3         255 --> CARLSSON JORGEN/AU
E4           1     CARLSSON JORGEN DR/AU
E5           1     CARLSSON JORGEN INGVAR/AU
E6           3     CARLSSON JORGEN PROF/AU
E7         270     CARLSSON K/AU
E8           3     CARLSSON K A/AU
E9           6     CARLSSON K B/AU
E10          9     CARLSSON K C/AU
E11          1     CARLSSON K C C/AU
E12          3     CARLSSON K E/AU

=> s e2-e6 and HER2
L1          47 ("CARLSSON JORG DR"/AU OR "CARLSSON JORGEN"/AU OR "CARLSSON JORG
               EN DR"/AU OR "CARLSSON JORGEN INGVAR"/AU OR "CARLSSON JORGEN
               PROF"/AU) AND HER2

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2           18 DUP REM L1 (29 DUPLICATES REMOVED)

=> s l2 and ((staphylococcal protein A)or SPA)
L3            0 L2 AND ((STAPHYLOCOCCAL PROTEIN A) OR SPA)

=> d l2 1-
YOU HAVE REQUESTED DATA FROM 18 ANSWERS - CONTINUE? Y/(N):y

L2   ANSWER 1 OF 18  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
     DUPLICATE 1
AN   2009:627745  BIOSIS <<LOGINID::20100301>>
DN   PREV200900628848
TI   Engineering and characterization of a bispecific   ***HER2***   x
     EGFR-binding affibody molecule.
AU   Friedman, Mikaela; Lindstrom, Sara; Ekerljung, Lina; Andersson-Svahn,
     Helene;   ***Carlsson, Jorgen***  ; Brismar, Hjalmar; Gedda, Lars; Frejd,
     Fredrik Y.; Stahl, Stefan [Reprint Author]
CS   AlbaNova Univ Ctr, Royal Inst Technol KTH, Div Mol Biotechnol, SE-10691
     Stockholm, Sweden
     stefan.stahl@biotech.kth.se
SO   Biotechnology and Applied Biochemistry, (OCT 2009) Vol. 54, No. Part 2,
     pp. 121-131.
     CODEN: BABIEC. ISSN: 0885-4513.
DT   Article
LA   English
ED   Entered STN: 18 Nov 2009
     Last Updated on STN: 18 Nov 2009

L2   ANSWER 2 OF 18  EMBASE  COPYRIGHT (c) 2010 Elsevier B.V. All rights
     reserved on STN                                        DUPLICATE 2
AN   2008123739  EMBASE   <<LOGINID::20100301>>
TI   EGFR,   ***HER2***  , and HER3 expression in laryngeal primary tumors and
     corresponding metastases.
AU   Wei, Qichun, Dr. (correspondence); Hu, Qiongge
```

CS Department of Radiation Oncology, Second Affiliated Hospital, Hangzhou, 310009, China. Qichun_Wei@zju.edu.cn
AU Wei, Qichun, Dr. (correspondence); Sheng, Liming; Shui, Yongjie
CS Cancer Institute, Zhejiang University, Hangzhou, 310009, China. Qichun_Wei@zju.edu.cn
AU Wei, Qichun, Dr. (correspondence); ***Carlsson, Jorgen***
CS Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University Hospital, SE-751 85, Uppsala, Sweden. Qichun_Wei@zju.edu.cn
AU Nordgren, Hans
CS Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University Hospital, SE-751 85, Uppsala, Sweden.
AU Wei, Qichun, Dr. (correspondence); Hu, Qiongge
CS Cancer Institute, Zhejiang University School of Medicine, Jiefang Road 88, Hangzhou, 310009, China. Qichun_Wei@zju.edu.cn
SO Annals of Surgical Oncology, (Apr 2008) Vol. 15, No. 4, pp. 1193-1201. Refs: 41
ISSN: 1068-9265; E-ISSN: 1534-4681 CODEN: ASONF4
CY United States
DT Journal; Conference Article; (Conference paper)
FS 011 Otorhinolaryngology
016 Cancer
029 Clinical and Experimental Biochemistry
005 General Pathology and Pathological Anatomy
LA English
SL English
ED Entered STN: 28 Mar 2008
Last Updated on STN: 28 Mar 2008

L2 ANSWER 3 OF 18 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN DUPLICATE 3
AN 2008241208 EMBASE <<LOGINID::20100301>>
TI Differences in radiosensitivity between three ***HER2*** overexpressing cell lines.
AU Steffen, Ann-Charlott; Tolmachev, Vladimir; Stenerlow, Bo; ***Carlsson,***
*** Jorgen (correspondence)***
CS Unit of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala 751 85, Sweden. Jorgen.Carlsson@bms.uu.se
AU Gostring, Lovisa
CS Affibody AB, Bromma 161 02, Sweden.
AU Palm, Stig
CS Department of Radiation Physics, Sahlgrenska Academy, Goteborg University, Goteborg 413 45, Sweden.
AU ***Carlsson, Jorgen (correspondence)***
CS Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala 751 85, Sweden. Jorgen.Carlsson@bms.uu.se
SO European Journal of Nuclear Medicine and Molecular Imaging, (Jun 2008) Vol. 35, No. 6, pp. 1179-1191. Refs: 40
ISSN: 1619-7070 CODEN: EJNMA6
CY Germany
DT Journal; Article
FS 023 Nuclear Medicine
029 Clinical and Experimental Biochemistry
LA English

SL English
ED Entered STN: 25 Jun 2008
Last Updated on STN: 25 Jun 2008

L2 ANSWER 4 OF 18 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
DUPLICATE 4
AN 2009:37285 BIOSIS <<LOGINID::20100301>>
DN PREV200900037285
TI Dimeric ***HER2*** -specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line.
AU Ekerljung, Lina [Reprint Author]; Lindborg, Malin; Gedda, Lars; Frejd, Fredrik Y.; ***Carlsson, Jorgen*** ; Lennartsson, Johan
CS Uppsala Univ, Dept Oncol Radiol and Clin Immunol, Div Biomed Radiat Sci, Rudbeck Lab, SE-75185 Uppsala, Sweden
Lina.Ekerljung@bms.uu.se
SO Biochemical and Biophysical Research Communications, (DEC 12 2008) Vol. 377, No. 2, pp. 489-494.
CODEN: BBRCA9. ISSN: 0006-291X.
DT Article
LA English
ED Entered STN: 31 Dec 2008
Last Updated on STN: 31 Dec 2008

L2 ANSWER 5 OF 18 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
DUPLICATE 5
AN 2007:286769 BIOSIS <<LOGINID::20100301>>
DN PREV200700282931
TI Radionuclide therapy of ***HER2*** -positive microxenografts using a Lu-177-labeled ***HER2*** -specific affibody molecule.
AU Tolmachev, Vladimir; Orlova, Anna; Pehrson, Rikard; Galli, Joakim; Baastrup, Barbro; Andersson, Karl; Sandstrom, Mattias; Rosik, Daniel; ***Carlsson, Jorgen*** ; Lundqvist, Hans; Wennborg, Anders; Nilsson, Fredrik Y. [Reprint Author]
CS Affibody AB, Box 20137, SE-16102 Bromma, Sweden
fredrik.nilsson@affibody.com
SO Cancer Research, (MAR 15 2007) Vol. 67, No. 6, pp. 2773-2782.
CODEN: CNREA8. ISSN: 0008-5472.
DT Article
LA English
ED Entered STN: 2 May 2007
Last Updated on STN: 2 May 2007

L2 ANSWER 6 OF 18 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
DUPLICATE 6
AN 2007:543629 BIOSIS <<LOGINID::20100301>>
DN PREV200700539165
TI EGFR, ***HER2*** and HER3 expression in esophageal primary tumours and corresponding metastases.
AU Wei, Qichun [Reprint Author]; Chen, Lirong; Sheng, Liming; Nordgren, Hans; Wester, Kenneth; ***Carlsson, Jorgen***
CS Zhejiang Univ, Sch Med, Inst Canc, Affiliated Hosp 2,Dept Radiat Oncol, Hangzhou 310009, Peoples R China
qichun.wei@bms.uu.se
SO International Journal of Oncology, (SEP 2007) Vol. 31, No. 3, pp. 493-499.
ISSN: 1019-6439.
DT Article
LA English

ED Entered STN: 17 Oct 2007
Last Updated on STN: 17 Oct 2007

L2 ANSWER 7 OF 18 SCISEARCH COPYRIGHT (c) 2010 The Thomson Corporation on STN
AN 2007:103732 SCISEARCH <<LOGINID::20100301>>
GA The Genuine Article (R) Number: 123TX
TI [Lu-177]pertuzumab: Experimental therapy of HER-2-expressing xenografts
AU Persson, Mikael (Reprint)
CS Uppsala Univ, Rudbeck Lab, Dept Biomed Radiat Sci, SE-75185 Uppsala, Sweden (Reprint)
AU Gedda, Lars; Lundqvist, Hans; Tolmachev, Vladimir; Nordgren, Hans; Malmstrom, Per-Uno; ***Carlsson, Jorgen***
CS Uppsala Univ, Rudbeck Lab, Dept Expt Urol, SE-75185 Uppsala, Sweden; Uppsala Univ, Rudbeck Lab, Dept Mol & Morphol Pathol, SE-75185 Uppsala, Sweden
E-mail: mikael.persson@bms.uu.se; jorgen.carlsson@bms.uu.se
CYA Sweden
SO CANCER RESEARCH, (1 JAN 2007) Vol. 67, No. 1, pp. 326-331.
ISSN: 0008-5472.
PB AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA.
DT Article; Journal
LA English
REC Reference Count: 22
ED Entered STN: 1 Feb 2007
Last Updated on STN: 1 Feb 2007
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L2 ANSWER 8 OF 18 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN DUPLICATE 7
AN 2006208451 EMBASE <<LOGINID::20100301>>
TI Tumor imaging using a picomolar affinity ***HER2*** binding Affibody molecule.
AU Orlova, Anna; Magnusson, Mikaela; Eriksson, Tove L.J.; Nilsson, Martin; Larsson, Barbro; Hoiden-Guthenberg, Ingmarie; Tolmachev, Vladimir; Nilsson, Fredrik Y. (correspondence)
CS Affibody AB, Bromma, Sweden. fredrik.nilsson@affibody.se
AU Widstrom, Charles
CS Department of Hospital Physics, Uppsala University Hospital.
AU Orlova, Anna; ***Carlsson, Jorgen*** ; Tolmachev, Vladimir; Nilsson, Fredrik Y. (correspondence)
CS Department of Oncology, Radiology, and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden. fredrik.nilsson@affibody.se
AU Stahl, Stefan
CS Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology, Stockholm, Sweden.
AU Nilsson, Fredrik Y. (correspondence)
CS Affibody AB, Box 20137, SE-161 02 Bromma, Sweden. fredrik.nilsson@affibody.se
SO Cancer Research, (15 Apr 2006) Vol. 66, No. 8, pp. 4339-4348.
Refs: 48
ISSN: 0008-5472 CODEN: CNREA8
CY United States
DT Journal; Article
FS 016 Cancer

```
     023     Nuclear Medicine
     029     Clinical and Experimental Biochemistry
LA   English
SL   English
ED   Entered STN: 19 May 2006
     Last Updated on STN: 19 May 2006

L2   ANSWER 9 OF 18  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
AN   2006:587101  BIOSIS <<LOGINID::20100301>>
DN   PREV200600597727
TI   Imaging and therapeutic targeting of   ***HER2***  -positive tumors using
     Affibody molecules.
AU   Nilsson, Fredrik Y. [Reprint Author]; Orlova, Anna; Tolmachev, Vladimir;
     Lundqvist, Hans;   ***Carlsson, Jorgen***  ; Widstrom, Charles; Sandstrom,
     Matrias; Pehtson, Rikard; Stahl, Stefan; Wennborg, Anders; Wennborg,
     Anders; Feldwisch, Joachim
CS   BMS, Uppsala, Sweden
SO   Proceedings of the American Association for Cancer Research Annual
     Meeting, (APR 2006) Vol. 47, pp. 878.
     Meeting Info.: 97th Annual Meeting of the
     American-Association-for-Cancer-Research (AACR). Washington, DC, USA.
     April 01 -05, 2006. Amer Assoc Canc Res.
     ISSN: 0197-016X.
DT   Conference; (Meeting)
     Conference; Abstract; (Meeting Abstract)
LA   English
ED   Entered STN: 8 Nov 2006
     Last Updated on STN: 8 Nov 2006

L2   ANSWER 10 OF 18  EMBASE  COPYRIGHT (c) 2010 Elsevier B.V. All rights
     reserved on STN                                    DUPLICATE 8
AN   2006271370  EMBASE  <<LOGINID::20100301>>
TI   Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice.
AU   Steffen, Ann-Charlott (correspondence); Nilsson, Fredrik Y.; Tolmachev,
     Vladimir;   ***Carlsson, Jorgen***
CS   Department of Oncology, Radiology and Clinical Immunology, Rudbeck
     Laboratory, Uppsala University, 751 85 Uppsala, Sweden. ann-charlott.steff
     en@bms.uu.se
AU   Orlova, Anna; Nilsson, Fredrik Y.
CS   Affibody AB, Bromma, Sweden.
AU   Wikman, Maria; Stahl, Stefan
CS   Department of Molecular Biotechnology, AlbaNova University Center, Royal
     Institute of Technology (KTH), Stockholm, Sweden.
AU   Adams, Gregory P.
CS   Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA,
     United States.
SO   European Journal of Nuclear Medicine and Molecular Imaging, (Jun 2006)
     Vol. 33, No. 6, pp. 631-638.
     Refs: 32
     ISSN: 1619-7070  CODEN: EJNMA6
CY   Germany
DT   Journal; Article
FS   016     Cancer
     023     Nuclear Medicine
     030     Clinical and Experimental Pharmacology
     037     Drug Literature Index
LA   English
```

SL English
ED Entered STN: 21 Jun 2006
Last Updated on STN: 21 Jun 2006

L2 ANSWER 11 OF 18 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN DUPLICATE 9
AN 2008:7733 BIOSIS <<LOGINID::20100301>>
DN PREV200800009310
TI Comparative in vivo evaluation of technetium and iodine labels on an anti-***HER2*** Affibody for single-photon imaging of ***HER2*** expression in tumors.
AU Orlova, Anna; Nilsson, Fredrik Y.; Wikman, Maria; Widstrom, Charles; Stahl, Stefan; ***Carlsson, Jorgen*** ; Tolmachev, Vladimir [Reprint Author]
CS Uppsala Univ, Rudbeck Lab, Unit Biomed Radiat Sci, Dept Oncol Radiol and Clin Immunol, Uppsala 75185, Sweden
valdimir.tolmachev@bms.uu.se
SO Journal of Nuclear Medicine, (MAR 2006) Vol. 47, No. 3, pp. 512-519.
CODEN: JNMEAQ. ISSN: 0161-5505.
DT Article
LA English
ED Entered STN: 12 Dec 2007
Last Updated on STN: 12 Dec 2007

L2 ANSWER 12 OF 18 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN DUPLICATE 10
AN 2006372266 EMBASE <<LOGINID::20100301>>
TI Targeting the epidermal growth factor receptor family in radionuclide therapy of tumors-signal transduction and DNA repair.
AU Lennartsson, Johan (correspondence)
CS Ludwig Institute for Cancer Research, Uppsala University, Box 595, SE-751 24, Uppsala, Sweden. Johan.Lennartsson@LICR.uu.se
AU ***Carlsson, Jorgen*** ; Stenerlow, Bo
CS Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, SE-751 85, Uppsala, Sweden.
SO Letters in Drug Design and Discovery, (2006) Vol. 3, No. 6, pp. 357-368.
Refs: 171
ISSN: 1570-1808
CY Netherlands
DT Journal; General Review; (Review)
FS 014 Radiology
016 Cancer
029 Clinical and Experimental Biochemistry
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
LA English
SL English
ED Entered STN: 18 Aug 2006
Last Updated on STN: 18 Aug 2006

L2 ANSWER 13 OF 18 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN DUPLICATE 11
AN 2006240306 EMBASE <<LOGINID::20100301>>
TI Effects of ***HER2*** -binding affibody molecules on intracellular signaling pathways.
AU Ekerljung, Lina; Steffen, Ann-Charlott; ***Carlsson, Jorgen***
CS Department of Oncology, Radiology and Clinical Immunology, Rudbeck

Laboratory, Uppsala University, Uppsala, Sweden.
AU Lennartsson, Johan (correspondence)
CS Ludwig Institute for Cancer Research, Uppsala University, Uppsala, Sweden. Johan.Lennartsson@LICR.uu.se
AU Lennartsson, Johan (correspondence)
CS Ludwig Institute for Cancer Research, Uppsala University, Biomedical Center, SE-751 24 Uppsala, Sweden. Johan.Lennartsson@LICR.uu.se
SO Tumor Biology, (May 2006) Vol. 27, No. 4, pp. 201-210.
Refs: 28
ISSN: 1010-4283 CODEN: TUMBEA
CY Switzerland
DT Journal; Article
FS 037 Drug Literature Index
005 General Pathology and Pathological Anatomy
007 Pediatrics and Pediatric Surgery
LA English
SL English
ED Entered STN: 15 Jun 2006
Last Updated on STN: 15 Jun 2006

L2 ANSWER 14 OF 18 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN DUPLICATE 12
AN 2005:246126 BIOSIS <<LOGINID::20100301>>
DN PREV200510026707
TI Analysis of ***HER2*** expression in primary urinary bladder carcinoma and corresponding metastases.
AU Gardmark, Truls [Reprint Author]; Wester, Kenneth; Torre, Manuel De La; ***Carlsson, Jorgen*** ; Malmstrom, Per-Uno
CS Uppsala Univ, Akad Hosp, Dept Surg Sci, Div Urol, SE-75185 Uppsala, Sweden Truls.Gardmark@surgsci.uu.se
SO BJU International, (MAY 2005) Vol. 95, No. 7, pp. 982-986.
ISSN: 1464-4096.
DT Article
LA English
ED Entered STN: 29 Jun 2005
Last Updated on STN: 29 Jun 2005

L2 ANSWER 15 OF 18 EMBASE COPYRIGHT (c) 2010 Elsevier B.V. All rights reserved on STN DUPLICATE 13
AN 2005363617 EMBASE <<LOGINID::20100301>>
TI Cellular uptake of radioiodine delivered by trastuzumab can be modified by the addition of epidermal growth factor.
AU Nordberg, Erika (correspondence); Steffen, Ann-Charlott; Persson, Mikael; Sundberg, Asa L.; ***Carlsson, Jorgen***
CS Division of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, 751 85, Uppsala, Sweden. Erika.Nordberg@bms.uu.se
AU Persson, Mikael
CS Division of Experimental Urology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
AU Glimelius, Bengt
CS Division of Oncology, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden.
SO European Journal of Nuclear Medicine and Molecular Imaging, (Jul 2005) Vol. 32, No. 7, pp. 771-777.
Refs: 39
ISSN: 1619-7070 CODEN: EJNMA6

CY Germany
DT Journal; Article
FS 016 Cancer
023 Nuclear Medicine
037 Drug Literature Index
LA English
SL English
ED Entered STN: 27 Oct 2005
Last Updated on STN: 27 Oct 2005

L2 ANSWER 16 OF 18 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN DUPLICATE 14
AN 2005:434799 BIOSIS <<LOGINID::20100301>>
DN PREV200510218038
TI In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics.
AU Steffen, Ann-Charlott [Reprint Author]; Wikman, Maria; Tolmachev, Vladimir; Adams, Gregory P.; Nilsson, Fredrik Y.; Stahl, Stefan; ***Carlsson, Jorgen***
CS Uppsala Univ, Dept Oncol, Rudbeck Lab, Unit Biomed Radiat Sci, Hammarskolds Vag 20, S-75237 Uppsala, Sweden
ann-charlott.steffen@bms.uu.se
SO Cancer Biotherapy & Radiopharmaceuticals, (JUN 2005) Vol. 20, No. 3, pp. 239-248.
ISSN: 1084-9785.
DT Article
LA English
ED Entered STN: 26 Oct 2005
Last Updated on STN: 26 Oct 2005

L2 ANSWER 17 OF 18 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
AN 2009:389649 BIOSIS <<LOGINID::20100301>>
DN PREV200900390752
TI AFFIBODY (R) MOLECULES AS NEW POTENTIAL AGENTS FOR RADIONUCLIDE IMAGING AND THERAPY.
AU Orlova, Anna [Reprint Author]; Magnusson, Mikaela; Larsson, Barbro; Wikman, Maria; Steffen, Ann-Charlott; Nilsson, Martin; Stahl, Stefan; Tolmachev, Vladimir; ***Carlsson, Jorgen*** ; Nilsson, Fredrik
CS Affibody AB, SE-16102 Bromma, Sweden
SO Anticancer Research, (SEP-OCT 2004) Vol. 24, No. 5D, pp. 3686.
Meeting Info.: 7th International Congress of Anticancer Research. Corfu, GREECE. October 25 -30, 2004.
CODEN: ANTRD4. ISSN: 0250-7005.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 1 Jul 2009
Last Updated on STN: 1 Jul 2009

L2 ANSWER 18 OF 18 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN DUPLICATE 15
AN 2004:259300 BIOSIS <<LOGINID::20100301>>
DN PREV200400260223
TI Radiobromination of monoclonal antibody using potassium (76Br) (4 isothiocyanatobenzyl-ammonio)-bromo-decahydro-closo-dodecaborate (Bromo-DABI).

```
AU   Bruskin, Alexander; Sivaev, Igor; Persson, Mikael; Lundqvist, Hans;
       ***Carlsson, Jorgen***  ; Sjoberg, Stefan; Tolmachev, Vladimir [Reprint
     Author]
CS   Unit of Biomedical Radiation Sciences, Rudbecklaboratoriet, Uppsala
     University, S-751 85, Uppsala, Sweden
     Vladimir.Tolmachev@bms.uu.se
SO   Nuclear Medicine and Biology, (February 2004) Vol. 31, No. 2, pp. 205-211.
     print.
     ISSN: 0969-8051.
DT   Article
LA   English
ED   Entered STN: 19 May 2004
     Last Updated on STN: 19 May 2004


=> e stahl stefan/au
E1          55     STAHL SONJA/AU
E2           1     STAHL SR JAMES P/AU
E3         357 --> STAHL STEFAN/AU
E4           3     STAHL STEFAN DR/AU
E5           1     STAHL STEFAN KARL HEINZ/AU
E6          13     STAHL STEFAN W/AU
E7          22     STAHL STEFANIE/AU
E8           1     STAHL STEFANIE K/AU
E9           1     STAHL STEFEN/AU
E10          1     STAHL STEHEN M/AU
E11         10     STAHL STEN/AU
E12          1     STAHL STEN R/AU

=> s e3-e6 and HER2
L4          41 ("STAHL STEFAN"/AU OR "STAHL STEFAN DR"/AU OR "STAHL STEFAN KARL
               HEINZ"/AU OR "STAHL STEFAN W"/AU) AND HER2

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5           12 DUP REM L4 (29 DUPLICATES REMOVED)

=> d 1-
YOU HAVE REQUESTED DATA FROM 12 ANSWERS - CONTINUE? Y/(N):y

L5   ANSWER 1 OF 12  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
     DUPLICATE 1
AN   2009:627745  BIOSIS <<LOGINID::20100301>>
DN   PREV200900628848
TI   Engineering and characterization of a bispecific   ***HER2***   x
     EGFR-binding affibody molecule.
AU   Friedman, Mikaela; Lindstrom, Sara; Ekerljung, Lina; Andersson-Svahn,
     Helene; Carlsson, Jorgen; Brismar, Hjalmar; Gedda, Lars; Frejd, Fredrik
     Y.;   ***Stahl, Stefan***   [Reprint Author]
CS   AlbaNova Univ Ctr, Royal Inst Technol KTH, Div Mol Biotechnol, SE-10691
     Stockholm, Sweden
     stefan.stahl@biotech.kth.se
SO   Biotechnology and Applied Biochemistry, (OCT 2009) Vol. 54, No. Part 2,
     pp. 121-131.
     CODEN: BABIEC. ISSN: 0885-4513.
DT   Article
LA   English
```

ED Entered STN: 18 Nov 2009
Last Updated on STN: 18 Nov 2009

L5 ANSWER 2 OF 12 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
DUPLICATE 2
AN 2009:350576 BIOSIS <<LOGINID::20100301>>
DN PREV200900351679
TI Engineered affinity proteins for tumour-targeting applications.
AU Friedman, Mikaela; ***Stahl, Stefan*** [Reprint Author]
CS Royal Inst Technol, AlbaNova Univ Ctr, Sch Biotechnol, Div Mol Biotechnol, SE-10691 Stockholm, Sweden
Stefar.stahl@biotech.kth.se
SO Biotechnology and Applied Biochemistry, (MAY 2009) Vol. 53, No. Part 1, pp. 1-29.
CODEN: BABIEC. ISSN: 0885-4513.
DT Article
General Review; (Literature Review)
LA English
ED Entered STN: 11 Jun 2009
Last Updated on STN: 11 Jun 2009

L5 ANSWER 3 OF 12 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
DUPLICATE 3
AN 2008:337162 BIOSIS <<LOGINID::20100301>>
DN PREV200800337161
TI Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule.
AU Friedman, Mikaela; Orlova, Anna; Johansson, Eva; Eriksson, Tove L. J.; Hoiden-Guthenberg, Ingmarie; Tolmachev, Vladimir; Nilsson, Fredrik Y.; ***Stahl, Stefan*** [Reprint Author]
CS Kungl Tekniska Hogskolan KTH, AlbaNova Univ Ctr, Dept Mol Biotechnol, SE-10691 Stockholm, Sweden
stefans@biotech.kth.se
SO Journal of Molecular Biology, (MAR 7 2008) Vol. 376, No. 5, pp. 1388-1402.
CODEN: JMOBAK. ISSN: 0022-2836.
DT Article
LA English
ED Entered STN: 5 Jun 2008
Last Updated on STN: 20 Aug 2008

L5 ANSWER 4 OF 12 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
DUPLICATE 4
AN 2009:33777 BIOSIS <<LOGINID::20100301>>
DN PREV200900033777
TI Epitope mapping of antibodies using bacterial surface display.
AU Rockberg, Johan; Lofblom, John; Hjelm, Barbara; Uhlen, Mathias [Reprint Author]; ***Stahl, Stefan***
CS Royal Inst Technol KTH, Dept Mol Biotechnol, AlbaNova Univ Ctr, Sch Biotechnol, SE-10691 Stockholm, Sweden
mathias@biotech.kth.se
SO Nature Methods, (DEC 2008) Vol. 5, No. 12, pp. 1039-1045.
ISSN: 1548-7091.
DT Article
LA English
ED Entered STN: 24 Dec 2008
Last Updated on STN: 24 Dec 2008

L5 ANSWER 5 OF 12 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
DUPLICATE 5
AN 2008:74017 BIOSIS <<LOGINID::20100301>>
DN PREV200800073809
TI Simplified characterization through site-specific protease-mediated release of affinity proteins selected by staphylococcal display.
AU Kronqvist, Nina; Lofblom, John; Severa, Denise; ***Stahl, Stefan*** ; Wernerus, Henrik [Reprint Author]
CS AlbaNova Univ Ctr, Royal Inst Technol, Sch Biotechnol, Dept Mol Biotechnol, Roslagstullsbacken 16, SE-10691 Stockholm, Sweden henrik@biotech.kth.se
SO FEMS Microbiology Letters, (JAN 2008) Vol. 278, No. 1, pp. 128-136. CODEN: FMLED7. ISSN: 0378-1097.
DT Article
LA English
ED Entered STN: 16 Jan 2008
Last Updated on STN: 16 Jan 2008

L5 ANSWER 6 OF 12 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
DUPLICATE 6
AN 2006:397535 BIOSIS <<LOGINID::20100301>>
DN PREV200600389717
TI Tumor Imaging using a picomolar affinity ***HER2*** binding affibody molecule.
AU Orlova, Anna; Magnusson, Mikaela; Eriksson, Tove L.J.; Nilsson, Martin; Larsson, Barbro; Holden-Guthenherg, Ingmarie; Widstroem, Charles; Carlsson, Joergen; Tolmachev, Vladimir; ***Stahl, Stefan*** ; Nilsson, Fredrik Y. [Reprint Author]
CS Affibody AB, Box 20137, SE-16102 Bromma, Sweden fredriknilsson@affibody.se
SO Cancer Research, (APR 15 2006) Vol. 66, No. 8, pp. 4339-4348. CODEN: CNREA8. ISSN: 0008-5472.
DT Article
LA English
ED Entered STN: 9 Aug 2006
Last Updated on STN: 9 Aug 2006

L5 ANSWER 7 OF 12 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
AN 2006:587101 BIOSIS <<LOGINID::20100301>>
DN PREV200600597727
TI Imaging and therapeutic targeting of ***HER2*** -positive tumors using Affibody molecules.
AU Nilsson, Fredrik Y. [Reprint Author]; Orlova, Anna; Tolmachev, Vladimir; Lundqvist, Hans; Carlsson, Jorgen; Widstrom, Charles; Sandstrom, Matrias; Pehtson, Rikard; ***Stahl, Stefan*** ; Wennborg, Anders; Wennborg, Anders; Feldwisch, Joachim
CS BMS, Uppsala, Sweden
SO Proceedings of the American Association for Cancer Research Annual Meeting, (APR 2006) Vol. 47, pp. 878.
Meeting Info.: 97th Annual Meeting of the American-Association-for-Cancer-Research (AACR). Washington, DC, USA. April 01 -05, 2006. Amer Assoc Canc Res.
ISSN: 0197-016X.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 8 Nov 2006

Last Updated on STN: 8 Nov 2006

L5 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN DUPLICATE 7
AN 2006:526929 CAPLUS <<LOGINID::20100301>>
DN 145:511264
TI Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice
AU Steffen, Ann-Charlott; Orlova, Anna; Wikman, Maria; Nilsson, Fredrik Y.; ***Stahl, Stefan*** ; Adams, Gregory P.; Tolmachev, Vladimir; Carlsson, Joergen
CS Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Swed.
SO European Journal of Nuclear Medicine and Molecular Imaging (2006), 33(6), 631-638
CODEN: EJNMA6; ISSN: 1619-7070
PB Springer
DT Journal
LA English
OSC.G 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 12 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN DUPLICATE 8
AN 2008:7733 BIOSIS <<LOGINID::20100301>>
DN PREV200800009310
TI Comparative in vivo evaluation of technetium and iodine labels on an anti-***HER2*** Affibody for single-photon imaging of ***HER2*** expression in tumors.
AU Orlova, Anna; Nilsson, Fredrik Y.; Wikman, Maria; Widstrom, Charles; ***Stahl, Stefan*** ; Carlsson, Jorgen; Tolmachev, Vladimir [Reprint Author]
CS Uppsala Univ, Rudbeck Lab, Unit Biomed Radiat Sci, Dept Oncol Radiol and Clin Immunol, Uppsala 75185, Sweden
valdimir.tolmachev@bms.uu.se
SO Journal of Nuclear Medicine, (MAR 2006) Vol. 47, No. 3, pp. 512-519.
CODEN: JNMEAQ. ISSN: 0161-5505.
DT Article
LA English
ED Entered STN: 12 Dec 2007
Last Updated on STN: 12 Dec 2007

L5 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2005:34770 CAPLUS <<LOGINID::20100301>>
DN 142:109117
TI Her-2 receptor-binding derivatives of Staphylococcal protein A for use in diagnosis and therapy of cancer
IN Carlsson, Joergen; ***Stahl, Stefan*** ; Eriksson, Tove; Gunneriusson, Elin; Nilsson, Fredrik
PA Affibody AB, Swed.
SO PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005003156	A1	20050113	WO 2004-SE1049	20040630

```
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
            LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
            TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
            SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
            SN, TD, TG
     AU 2004253835        A1    20050113    AU 2004-253835         20040630
     AU 2004253835        B2    20090129
     CA 2531238           A1    20050113    CA 2004-2531238        20040630
     EP 1641818           A1    20060405    EP 2004-749087         20040630
     EP 1641818           B1    20081203
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
     CN 1816563           A     20060809    CN 2004-80019059       20040630
     JP 2007537700        T     20071227    JP 2006-518586         20040630
     AT 416190            T     20081215    AT 2004-749087         20040630
     ES 2319426           T3    20090507    ES 2004-749087         20040630
     IN 2005KN02544       A     20061013    IN 2005-KN2544         20051209
     US 20100048868       A1    20100225    US 2006-563310         20060512
PRAI SE 2003-1987         A     20030704
     SE 2004-275          A     20040209
     WO 2004-SE1049       W     20040630
OSC.G   5     THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT  6     THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5   ANSWER 11 OF 12  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on
     STN                                                  DUPLICATE 9
AN   2005:434799  BIOSIS <<LOGINID::20100301>>
DN   PREV200510218038
TI   In vitro characterization of a bivalent anti-HER-2 affibody with potential
     for radionuclide-based diagnostics.
AU   Steffen, Ann-Charlott [Reprint Author]; Wikman, Maria; Tolmachev,
     Vladimir; Adams, Gregory P.; Nilsson, Fredrik Y.;   ***Stahl, Stefan***  ;
     Carlsson, Jorgen
CS   Uppsala Univ, Dept Oncol, Rudbeck Lab, Unit Biomed Radiat Sci,
     Hammarskolds Vag 20, S-75237 Uppsala, Sweden
     ann-charlott.steffen@bms.uu.se
SO   Cancer Biotherapy & Radiopharmaceuticals, (JUN 2005) Vol. 20, No. 3, pp.
     239-248.
     ISSN: 1084-9785.
DT   Article
LA   English
ED   Entered STN: 26 Oct 2005
     Last Updated on STN: 26 Oct 2005

L5   ANSWER 12 OF 12  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on
     STN
AN   2009:389649  BIOSIS <<LOGINID::20100301>>
DN   PREV200900390752
TI   AFFIBODY (R) MOLECULES AS NEW POTENTIAL AGENTS FOR RADIONUCLIDE IMAGING
     AND THERAPY.
```

```
AU   Orlova, Anna [Reprint Author]; Magnusson, Mikaela; Larsson, Barbro;
     Wikman, Maria; Steffen, Ann-Charlott; Nilsson, Martin;   ***Stahl,***
  ***     Stefan***  ; Tolmachev, Vladimir; Carlsson, Jorgen; Nilsson, Fredrik
CS   Affibody AB, SE-16102 Bromma, Sweden
SO   Anticancer Research, (SEP-OCT 2004) Vol. 24, No. 5D, pp. 3686.
     Meeting Info.: 7th International Congress of Anticancer Research. Corfu,
     GREECE. October 25 -30, 2004.
     CODEN: ANTRD4. ISSN: 0250-7005.
DT   Conference; (Meeting)
     Conference; Abstract; (Meeting Abstract)
LA   English
ED   Entered STN: 1 Jul 2009
     Last Updated on STN: 1 Jul 2009


=> e eriksson tove/au
E1          23     ERIKSSON TORNY/AU
E2          61     ERIKSSON TORSTEN/AU
E3           3 --> ERIKSSON TOVE/AU
E4          30     ERIKSSON TOVE L J/AU
E5           1     ERIKSSON TOVE L J DR/AU
E6           5     ERIKSSON TOVE LISA JENNY/AU
E7           3     ERIKSSON TRYGGVE/AU
E8           1     ERIKSSON TUA/AU
E9         835     ERIKSSON U/AU
E10          3     ERIKSSON U */AU
E11          3     ERIKSSON U B/AU
E12          6     ERIKSSON U DR/AU

=> s e3-e6 and HER2
L6          11 ("ERIKSSON TOVE"/AU OR "ERIKSSON TOVE L J"/AU OR "ERIKSSON TOVE
               L J DR"/AU OR "ERIKSSON TOVE LISA JENNY"/AU) AND HER2

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7            3 DUP REM L6 (8 DUPLICATES REMOVED)

=> d 1-
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L7   ANSWER 1 OF 3  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
     DUPLICATE 1
AN   2008:337162  BIOSIS <<LOGINID::20100301>>
DN   PREV200800337161
TI   Directed evolution to low nanomolar affinity of a tumor-targeting
     epidermal growth factor receptor-binding affibody molecule.
AU   Friedman, Mikaela; Orlova, Anna; Johansson, Eva;   ***Eriksson, Tove L.***
  ***     J.***  ; Hoiden-Guthenberg, Ingmarie; Tolmachev, Vladimir; Nilsson,
     Fredrik Y.; Stahl, Stefan [Reprint Author]
CS   Kungl Tekniska Hogskolan KTH, AlbaNova Univ Ctr, Dept Mol Biotechnol,
     SE-10691 Stockholm, Sweden
     stefans@biotech.kth.se
SO   Journal of Molecular Biology, (MAR 7 2008) Vol. 376, No. 5, pp. 1388-1402.
     CODEN: JMOBAK. ISSN: 0022-2836.
DT   Article
LA   English
ED   Entered STN: 5 Jun 2008
```

Last Updated on STN: 20 Aug 2008

L7 ANSWER 2 OF 3 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
DUPLICATE 2
AN 2006:397535 BIOSIS <<LOGINID::20100301>>
DN PREV200600389717
TI Tumor Imaging using a picomolar affinity ***HER2*** binding affibody molecule.
AU Orlova, Anna; Magnusson, Mikaela; ***Eriksson, Tove L.J.*** ; Nilsson, Martin; Larsson, Barbro; Holden-Guthenherg, Ingmarie; Widstroem, Charles; Carlsson, Joergen; Tolmachev, Vladimir; Stahl, Stefan; Nilsson, Fredrik Y. [Reprint Author]
CS Affibody AB, Box 20137, SE-16102 Bromma, Sweden
fredriknilsson@affibody.se
SO Cancer Research, (APR 15 2006) Vol. 66, No. 8, pp. 4339-4348.
CODEN: CNREA8. ISSN: 0008-5472.
DT Article
LA English
ED Entered STN: 9 Aug 2006
Last Updated on STN: 9 Aug 2006

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2005:34770 CAPLUS <<LOGINID::20100301>>
DN 142:109117
TI Her-2 receptor-binding derivatives of Staphylococcal protein A for use in diagnosis and therapy of cancer
IN Carlsson, Joergen; Stahl, Stefan; ***Eriksson, Tove*** ; Gunneriusson, Elin; Nilsson, Fredrik
PA Affibody AB, Swed.
SO PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005003156	A1	20050113	WO 2004-SE1049	20040630
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004253835	A1	20050113	AU 2004-253835	20040630
AU 2004253835	B2	20090129		
CA 2531238	A1	20050113	CA 2004-2531238	20040630
EP 1641818	A1	20060405	EP 2004-749087	20040630
EP 1641818	B1	20081203		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1816563	A	20060809	CN 2004-80019059	20040630
JP 2007537700	T	20071227	JP 2006-518586	20040630

```
     AT 416190            T     20081215    AT 2004-749087         20040630
     ES 2319426           T3    20090507    ES 2004-749087         20040630
     IN 2005KN02544       A     20061013    IN 2005-KN2544         20051209
     US 20100048868       A1    20100225    US 2006-563310         20060512
PRAI SE 2003-1987         A     20030704
     SE 2004-275          A     20040209
     WO 2004-SE1049       W     20040630
OSC.G   5     THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT  6     THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> e gunneriusson elin
E1          51     GUNNERI/BI
E2           2     GUNNERIS/BI
E3           0 --> GUNNERIUSSON ELIN/BI
E4           1     GUNNEROIDES/BI
E5          59     GUNNERS/BI
E6           2     GUNNERSBURY/BI
E7           5     GUNNERSEN/BI
E8           8     GUNNERSIDE/BI
E9           4     GUNNERSON/BI
E10          1     GUNNERT/BI
E11        336     GUNNERUS/BI
E12          1     GUNNERUSENSIS/BI

=> s e1-e12 and HER2
L8           0 (GUNNERI/BI OR GUNNERIS/BI OR "GUNNERIUSSON ELIN"/BI OR GUNNEROI
               DES/BI OR GUNNERS/BI OR GUNNERSBURY/BI OR GUNNERSEN/BI OR GUNNER
               SIDE/BI OR GUNNERSON/BI OR GUNNERT/BI OR GUNNERUS/BI OR GUNNERUS
               ENSIS/BI) AND HER2

=> e nilsson fredrik/au
E1           3     NILSSON FREDRICK/AU
E2           1     NILSSON FREDRIE/AU
E3         124 --> NILSSON FREDRIK/AU
E4           1     NILSSON FREDRIK DR/AU
E5           1     NILSSON FREDRIK L A/AU
E6           2     NILSSON FREDRIK O L/AU
E7           2     NILSSON FREDRIK OLOF LAURENTIUS/AU
E8           1     NILSSON FREDRIK SVEN/AU
E9          56     NILSSON FREDRIK Y/AU
E10          8     NILSSON FRIDA/AU
E11          2     NILSSON FRITIOF/AU
E12          1     NILSSON FRITZ/AU

=> s e1-e9 and HER2
L9          53 ("NILSSON FREDRICK"/AU OR "NILSSON FREDRIE"/AU OR "NILSSON FREDR
               IK"/AU OR "NILSSON FREDRIK DR"/AU OR "NILSSON FREDRIK L A"/AU
               OR "NILSSON FREDRIK O L"/AU OR "NILSSON FREDRIK OLOF LAURENTIUS"
               /AU OR "NILSSON FREDRIK SVEN"/AU OR "NILSSON FREDRIK Y"/AU) AND
               HER2

=> dup rem l9
PROCESSING COMPLETED FOR L9
L10          14 DUP REM L9 (39 DUPLICATES REMOVED)
```

```
=> d 1-
YOU HAVE REQUESTED DATA FROM 14 ANSWERS - CONTINUE? Y/(N):y

L10  ANSWER 1 OF 14  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
     DUPLICATE 1
AN   2008:337162  BIOSIS <<LOGINID::20100301>>
DN   PREV200800337161
TI   Directed evolution to low nanomolar affinity of a tumor-targeting
     epidermal growth factor receptor-binding affibody molecule.
AU   Friedman, Mikaela; Orlova, Anna; Johansson, Eva; Eriksson, Tove L. J.;
     Hoiden-Guthenberg, Ingmarie; Tolmachev, Vladimir;   ***Nilsson, Fredrik***
  ***      Y.***  ; Stahl, Stefan [Reprint Author]
CS   Kungl Tekniska Hogskolan KTH, AlbaNova Univ Ctr, Dept Mol Biotechnol,
     SE-10691 Stockholm, Sweden
     stefans@biotech.kth.se
SO   Journal of Molecular Biology, (MAR 7 2008) Vol. 376, No. 5, pp. 1388-1402.
     CODEN: JMOBAK. ISSN: 0022-2836.
DT   Article
LA   English
ED   Entered STN: 5 Jun 2008
     Last Updated on STN: 20 Aug 2008

L10  ANSWER 2 OF 14  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
     DUPLICATE 2
AN   2007:286769  BIOSIS <<LOGINID::20100301>>
DN   PREV200700282931
TI   Radionuclide therapy of   ***HER2***  -positive microxenografts using a
     Lu-177-labeled   ***HER2***  -specific affibody molecule.
AU   Tolmachev, Vladimir; Orlova, Anna; Pehrson, Rikard; Galli, Joakim;
     Baastrup, Barbro; Andersson, Karl; Sandstrom, Mattias; Rosik, Daniel;
     Carlsson, Jorgen; Lundqvist, Hans; Wennborg, Anders;   ***Nilsson,
Fredrik***
  ***      Y.***   [Reprint Author]
CS   Affibody AB, Box 20137, SE-16102 Bromma, Sweden
     fredrik.nilsson@affibody.com
SO   Cancer Research, (MAR 15 2007) Vol. 67, No. 6, pp. 2773-2782.
     CODEN: CNREA8. ISSN: 0008-5472.
DT   Article
LA   English
ED   Entered STN: 2 May 2007
     Last Updated on STN: 2 May 2007

L10  ANSWER 3 OF 14  BIOSIS  COPYRIGHT (c) 2010 The Thomson Corporation  on STN
     DUPLICATE 3
AN   2007:242720  BIOSIS <<LOGINID::20100301>>
DN   PREV200700233657
TI   Synthetic affibody molecules: A novel class of affinity ligands for
     molecular imaging of   ***HER2***  -expressing malignant tumors.
AU   Orlova, Anna; Tolmachev, Vladimir; Pehrson, Rikard; Lindborg, Malin; Tran,
     Thuy; Sandstrom, Mattias;   ***Nilsson, Fredrik Y.***  ; Wennborg, Anders;
     Abrahmsen, Lars; Feldwisch, Joachim [Reprint Author]
CS   Affibody AB, Voltavagen 13,POB 20137, SE-16102 Bromma, Sweden
     joachim.feldwisch@affibody.com
SO   Cancer Research, (MAR 1 2007) Vol. 67, No. 5, pp. 2178-2186.
     CODEN: CNREA8. ISSN: 0008-5472.
DT   Article
LA   English
```

ED Entered STN: 11 Apr 2007
Last Updated on STN: 11 Jul 2007

L10 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2010 ACS on STN DUPLICATE 4
AN 2007:328411 CAPLUS <<LOGINID::20100301>>
DN 147:85823
TI Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy
AU Tolmachev, Vladimir; Orlova, Anna; ***Nilsson, Fredrik Y.*** ; Feldwisch, Joachim; Wennborg, Anders; Abrahmsen, Lars
CS Affibody AB, Bromma, SE-161 02, Swed.
SO Expert Opinion on Biological Therapy (2007), 7(4), 555-568
CODEN: EOBTA2; ISSN: 1471-2598
PB Informa Healthcare
DT Journal; General Review
LA English
OSC.G 33 THERE ARE 33 CAPLUS RECORDS THAT CITE THIS RECORD (33 CITINGS)
RE.CNT 106 THERE ARE 106 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2010 ACS on STN DUPLICATE 5
AN 2007:407442 CAPLUS <<LOGINID::20100301>>
DN 146:457571
TI Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy
AU ***Nilsson, Fredrik Y.*** ; Tolmachev, Vladimir
CS Affibody AB, Bromma, SE-161 02, Swed.
SO Current Opinion in Drug Discovery & Development (2007), 10(2), 167-175
CODEN: CODDFF; ISSN: 1367-6733
PB Thomson Scientific
DT Journal; General Review
LA English
OSC.G 31 THERE ARE 31 CAPLUS RECORDS THAT CITE THIS RECORD (31 CITINGS)
RE.CNT 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 14 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN DUPLICATE 6
AN 2006:397535 BIOSIS <<LOGINID::20100301>>
DN PREV200600389717
TI Tumor Imaging using a picomolar affinity ***HER2*** binding affibody molecule.
AU Orlova, Anna; Magnusson, Mikaela; Eriksson, Tove L.J.; Nilsson, Martin; Larsson, Barbro; Holden-Guthenherg, Ingmarie; Widstroem, Charles; Carlsson, Joergen; Tolmachev, Vladimir; Stahl, Stefan; ***Nilsson,*** *** Fredrik Y.*** [Reprint Author]
CS Affibody AB, Box 20137, SE-16102 Bromma, Sweden
fredriknilsson@affibody.se
SO Cancer Research, (APR 15 2006) Vol. 66, No. 8, pp. 4339-4348.
CODEN: CNREA8. ISSN: 0008-5472.
DT Article
LA English
ED Entered STN: 9 Aug 2006
Last Updated on STN: 9 Aug 2006

L10 ANSWER 7 OF 14 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
AN 2006:587101 BIOSIS <<LOGINID::20100301>>

DN PREV200600597727
TI Imaging and therapeutic targeting of ***HER2*** -positive tumors using Affibody molecules.
AU ***Nilsson, Fredrik Y.*** [Reprint Author]; Orlova, Anna; Tolmachev, Vladimir; Lundqvist, Hans; Carlsson, Jorgen; Widstrom, Charles; Sandstrom, Matrias; Pehtson, Rikard; Stahl, Stefan; Wennborg, Anders; Wennborg, Anders; Feldwisch, Joachim
CS BMS, Uppsala, Sweden
SO Proceedings of the American Association for Cancer Research Annual Meeting, (APR 2006) Vol. 47, pp. 878.
Meeting Info.: 97th Annual Meeting of the American-Association-for-Cancer-Research (AACR). Washington, DC, USA. April 01 -05, 2006. Amer Assoc Canc Res.
ISSN: 0197-016X.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 8 Nov 2006
Last Updated on STN: 8 Nov 2006

L10 ANSWER 8 OF 14 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN DUPLICATE 7
AN 2006:466033 BIOSIS <<LOGINID::20100301>>
DN PREV200600473509
TI In-111-benzyl-DTPA-Z(***HER2*** : 342), an affibody-based conjugate for in vivo imaging of ***HER2*** expression in malignant tumors.
AU Tolmachev, Vladimir [Reprint Author]; ***Nilsson, Fredrik Y.*** ; Widstrom, Charles; Andersson, Karl; Rosik, Daniel; Gedda, Lars; Wennborg, Anders; Orlova, Anna
CS Univ Uppsala, Rudbeck Lab, Div Biomed Radiat Sci, S-75185 Uppsala, Sweden
vladimir.tolmachev@bms.uu.se
SO Journal of Nuclear Medicine, (MAY 2006) Vol. 47, No. 5, pp. 846-853.
CODEN: JNMEAQ. ISSN: 0161-5505.
DT Article
LA English
ED Entered STN: 20 Sep 2006
Last Updated on STN: 20 Sep 2006

L10 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2010 ACS on STN DUPLICATE 8
AN 2006:526929 CAPLUS <<LOGINID::20100301>>
DN 145:511264
TI Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice
AU Steffen, Ann-Charlott; Orlova, Anna; Wikman, Maria; ***Nilsson, Fredrik*** *** Y.*** ; Stahl, Stefan; Adams, Gregory P.; Tolmachev, Vladimir; Carlsson, Joergen
CS Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Swed.
SO European Journal of Nuclear Medicine and Molecular Imaging (2006), 33(6), 631-638
CODEN: EJNMA6; ISSN: 1619-7070
PB Springer
DT Journal
LA English
OSC.G 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 14 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN DUPLICATE 9
AN 2008:7733 BIOSIS <<LOGINID::20100301>>
DN PREV200800009310
TI Comparative in vivo evaluation of technetium and iodine labels on an anti-***HER2*** Affibody for single-photon imaging of ***HER2*** expression in tumors.
AU Orlova, Anna; ***Nilsson, Fredrik Y.*** ; Wikman, Maria; Widstrom, Charles; Stahl, Stefan; Carlsson, Jorgen; Tolmachev, Vladimir [Reprint Author]
CS Uppsala Univ, Rudbeck Lab, Unit Biomed Radiat Sci, Dept Oncol Radiol and Clin Immunol, Uppsala 75185, Sweden
valdimir.tolmachev@bms.uu.se
SO Journal of Nuclear Medicine, (MAR 2006) Vol. 47, No. 3, pp. 512-519.
CODEN: JNMEAQ. ISSN: 0161-5505.
DT Article
LA English
ED Entered STN: 12 Dec 2007
Last Updated on STN: 12 Dec 2007

L10 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2005:34770 CAPLUS <<LOGINID::20100301>>
DN 142:109117
TI Her-2 receptor-binding derivatives of Staphylococcal protein A for use in diagnosis and therapy of cancer
IN Carlsson, Joergen; Stahl, Stefan; Eriksson, Tove; Gunneriusson, Elin; ***Nilsson, Fredrik***
PA Affibody AB, Swed.
SO PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005003156	A1	20050113	WO 2004-SE1049	20040630
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004253835	A1	20050113	AU 2004-253835	20040630
AU 2004253835	B2	20090129		
CA 2531238	A1	20050113	CA 2004-2531238	20040630
EP 1641818	A1	20060405	EP 2004-749087	20040630
EP 1641818	B1	20081203		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1816563	A	20060809	CN 2004-80019059	20040630

JP 2007537700	T	20071227	JP 2006-518586	20040630
AT 416190	T	20081215	AT 2004-749087	20040630
ES 2319426	T3	20090507	ES 2004-749087	20040630
IN 2005KN02544	A	20061013	IN 2005-KN2544	20051209
US 20100048868	A1	20100225	US 2006-563310	20060512
PRAI SE 2003-1987	A	20030704		
SE 2004-275	A	20040209		
WO 2004-SE1049	W	20040630		

OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2010 ACS on STN DUPLICATE 10
AN 2005:1145736 CAPLUS <<LOGINID::20100301>>
DN 144:47348
TI Evaluation of ((4-Hydroxyphenyl)ethyl)maleimide for Site-Specific Radiobromination of Anti- ***HER2*** Affibody
AU Mume, Eskender; Orlova, Anna; Larsson, Barbro; Nilsson, Ann-Sofie; ***Nilsson, Fredrik Y.*** ; Sjoeberg, Stefan; Tolmachev, Vladimir
CS Department of Chemistry, Organic Chemistry, Uppsala University, Uppsala, Swed.
SO Bioconjugate Chemistry (2005), 16(6), 1547-1555
CODEN: BCCHES; ISSN: 1043-1802
PB American Chemical Society
DT Journal
LA English
OSC.G 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 13 OF 14 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN DUPLICATE 11
AN 2005:434799 BIOSIS <<LOGINID::20100301>>
DN PREV200510218038
TI In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics.
AU Steffen, Ann-Charlott [Reprint Author]; Wikman, Maria; Tolmachev, Vladimir; Adams, Gregory P.; ***Nilsson, Fredrik Y.*** ; Stahl, Stefan; Carlsson, Jorgen
CS Uppsala Univ, Dept Oncol, Rudbeck Lab, Unit Biomed Radiat Sci, Hammarskolds Vag 20, S-75237 Uppsala, Sweden
ann-charlott.steffen@bms.uu.se
SO Cancer Biotherapy & Radiopharmaceuticals, (JUN 2005) Vol. 20, No. 3, pp. 239-248.
ISSN: 1084-9785.
DT Article
LA English
ED Entered STN: 26 Oct 2005
Last Updated on STN: 26 Oct 2005

L10 ANSWER 14 OF 14 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
AN 2009:389649 BIOSIS <<LOGINID::20100301>>
DN PREV200900390752
TI AFFIBODY (R) MOLECULES AS NEW POTENTIAL AGENTS FOR RADIONUCLIDE IMAGING AND THERAPY.
AU Orlova, Anna [Reprint Author]; Magnusson, Mikaela; Larsson, Barbro;

Wikman, Maria; Steffen, Ann-Charlott; Nilsson, Martin; Stahl, Stefan; Tolmachev, Vladimir; Carlsson, Jorgen; ***Nilsson, Fredrik***
CS Affibody AB, SE-16102 Bromma, Sweden
SO Anticancer Research, (SEP-OCT 2004) Vol. 24, No. 5D, pp. 3686. Meeting Info.: 7th International Congress of Anticancer Research. Corfu, GREECE. October 25 -30, 2004. CODEN: ANTRD4. ISSN: 0250-7005.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 1 Jul 2009
Last Updated on STN: 1 Jul 2009

=> s HER2 and staphylo?
L11 97 HER2 AND STAPHYLO?

=> dup rem l11
PROCESSING COMPLETED FOR L11
L12 53 DUP REM L11 (44 DUPLICATES REMOVED)

=> s l12 and (substitut? or mutat?)
L13 11 L12 AND (SUBSTITUT? OR MUTAT?)

=> d bib ab kwic 1-
YOU HAVE REQUESTED DATA FROM 11 ANSWERS - CONTINUE? Y/(N):y

L13 ANSWER 1 OF 11 BIOSIS COPYRIGHT (c) 2010 The Thomson Corporation on STN
AN 2000:313922 BIOSIS <<LOGINID::20100301>>
DN PREV200000313922
TI Minimal catalytic domain of N-acetylglucosaminyltransferase V.
AU Korczak, Bozena [Reprint author]; Le, Thuyanh; Elowe, Sabine; Datti, Alessandro; Dennis, James W.
CS GlycoDesign Inc., 480 University Avenue, Suite 900, Toronto, Ontario, Canada
SO Glycobiology, (June, 2000) Vol. 10, No. 6, pp. 595-599. print. ISSN: 0959-6658.
DT Article
LA English
ED Entered STN: 26 Jul 2000
Last Updated on STN: 7 Jan 2002
AB UDP-GlcNAc: Manalpha1-6Manbeta-R beta1-6 N-acetylglucosaminyltransferase V (EC 2.4.1.155, GlcNAc-TV) is a Golgi enzyme that ***substitutes*** the trimannosyl core in the biosynthetic pathway for complex-type N-linked glycans. GlcNAc-TV activity is regulated by oncogenes frequently activated in cancer cells (ras, src, and ***her2*** /neu) and by activators of T lymphocytes. Overexpression of GlcNAc-TV in epithelial cells results in morphological transformation, while tumor cell mutants selected for loss of GlcNAc-TV products show diminished malignant potential in mice. In this report, we have expressed and characterized a series of N- and C-terminal deletions of GlcNAc-TV. Portions of GlcNAc-TV sequence were fused at the N-terminal domain to IgG-binding domains of ***staphylococcal*** Protein A and expressed in CHOP cells. The secreted fusion proteins were purified by IgG Sepharose affinity chromatography and assayed for enzyme activities. The peptide sequence S213-740 of GlcNAc-TV was determined to be essential for the catalytic activity, the remaining amino acids comprising a 183 amino acid stem

region, a 17 amino acid transmembrane domain and a 12 amino acid cytosolic moiety. Further deletion of 5 amino acids to produce peptide R218-740 reduced enzyme activity by 20-fold. Similar Km and Vmax values for donor and acceptor were observed for peptide S213-740, the minimal catalytic domain, and peptide Q39-740, which also included the stem region. Truncation of five amino acids from the C-terminus also resulted in a 20-fold loss of catalytic activity. Secondary structure predictions suggest a high frequency of turns in the stem region, and more contiguous stretches of alpha-helix found in the catalytic domain.

AB UDP-GlcNAc: Manalpha1-6Manbeta-R beta1-6 N-acetylglucosaminyltransferase V (EC 2.4.1.155, GlcNAc-TV) is a Golgi enzyme that ***substitutes*** the trimannosyl core in the biosynthetic pathway for complex-type N-linked glycans. GlcNAc-TV activity is regulated by oncogenes frequently activated in cancer cells (ras, src, and ***her2*** /neu) and by activators of T lymphocytes. Overexpression of GlcNAc-TV in epithelial cells results in morphological transformation, while tumor cell mutants. . . N- and C-terminal deletions of GlcNAc-TV. Portions of GlcNAc-TV sequence were fused at the N-terminal domain to IgG-binding domains of ***staphylococcal*** Protein A and expressed in CHOP cells. The secreted fusion proteins were purified by IgG Sepharose affinity chromatography and assayed. . .

L13 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2009:1628475 CAPLUS <<LOGINID::20100301>>

DN 152:138376

TI Ligand-binding domains derived from the two .alpha.-helical B domain of ***Staphylococcal*** protein A

IN Zhang, Rong; Syud, Faisal Ahmed; Webster, Jack Mathew

PA General Electric Company, USA

SO U.S. Pat. Appl. Publ., 55pp., Cont.-in-part of U.S. Ser. No. 608,590.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20090325313	A1	20091231	US 2008-337945	20081218
	US 20080176278	A1	20080724	US 2006-608590	20061208
PRAI	US 2006-608590	A2	20061208		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB ***Substitution*** variants of the B domain of ***Staphylococcal*** protein A with altered ligand binding are described. The domain forms a ligand-binding domain from a pair of anti-parallel .alpha.-helixes. Binding affinity may be altered by the use of non-natural amino acids, such as .alpha.-amino isobutyric acid. These variants may be useful as anal. reagents. Peptides were synthesized by Fmoc chem. Peptides binding to the ***her2*** and IgG domains of a ***her2*** -IgG fusion proteins were identified by BIA core screening.

TI Ligand-binding domains derived from the two .alpha.-helical B domain of ***Staphylococcal*** protein A

AB ***Substitution*** variants of the B domain of ***Staphylococcal*** protein A with altered ligand binding are described. The domain forms a ligand-binding domain from a pair of anti-parallel .alpha.-helixes.. . . isobutyric acid. These variants may be useful as anal. reagents. Peptides were synthesized by Fmoc chem. Peptides binding to the ***her2*** and IgG domains of a ***her2*** -IgG fusion proteins were identified by BIA core screening.

IT Protein motifs
(B domain; ligand-binding domains derived from two .alpha.-helical B domain of ***Staphylococcal*** protein A)
IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(IgG, peptide ligands for; ligand-binding domains derived from two .alpha.-helical B domain of ***Staphylococcal*** protein A)
IT Amino acids
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(analogs, in B domain variants; ligand-binding domains derived from two .alpha.-helical B domain of ***Staphylococcal*** protein A)
IT Cyanine dyes
Fluorescent substances
Radioactive substances
(conjugates with ligand-binding peptides; ligand-binding domains derived from two .alpha.-helical B domain of ***Staphylococcal*** protein A)
IT Protein sequences
.alpha.-Helix
(ligand-binding domains derived from two .alpha.-helical B domain of ***Staphylococcal*** protein A)
IT ***Staphylococcal*** protein A
RL: ARU (Analytical role, unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(ligand-binding domains derived from two .alpha.-helical B domain of ***Staphylococcal*** protein A)
IT Epidermal growth factor receptors
neu (receptor)
RL: ANT (Analyte); ANST (Analytical study)
(peptide ligands for; ligand-binding domains derived from two .alpha.-helical B domain of ***Staphylococcal*** protein A)
IT 1203612-40-1D, ***substitution*** variants
RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)
(amino acid sequence, EGFR-binding peptide; ligand-binding domains derived from two .alpha.-helical B domain of ***Staphylococcal*** protein A)
IT 1203612-38-7
RL: PRP (Properties)
(amino acid sequence, EGFR-binding peptide; ligand-binding domains derived from two .alpha.-helical B domain of ***Staphylococcal*** protein A)
IT 1203612-37-6D, ***substitution*** variants 1203612-39-8D, ***substitution*** variants
RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)
(amino acid sequence, ***Her2*** -binding peptide; ligand-binding domains derived from two .alpha.-helical B domain of ***Staphylococcal*** protein A)
IT 1203612-41-2D, ***substitution*** variants
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; ligand-binding domains derived from two .alpha.-helical B domain of ***Staphylococcal*** protein A)
IT 13981-56-1D, Fluorine 18, peptide conjugates, uses 14133-76-7D,

Technetium 99, peptide conjugates, uses 14333-33-6D, Carbon-11, peptide conjugates, uses 14596-37-3D, Phosphorus 32, peptide conjugates, uses
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(ligand-binding domains derived from two .alpha.-helical B domain of ***Staphylococcal*** protein A)

IT 62-57-7, .alpha.-Amino isobutyric acid 1202694-17-4
RL: MSC (Miscellaneous)
(peptides contg.; ligand-binding domains derived from two .alpha.-helical B domain of ***Staphylococcal*** protein A)

IT 1203612-43-4 1203612-44-5 1203612-45-6 1203612-46-7 1203612-47-8 1203612-48-9 1203612-49-0 1203612-50-3 1203612-51-4 1203612-52-5 1203612-53-6 1203612-54-7 1203612-55-8 1203612-56-9 1203612-57-0 1203612-58-1 1203612-59-2 1203612-60-5 1203612-61-6 1203612-62-7 1203612-63-8 1203612-64-9 1203612-65-0 1203612-66-1 1203612-67-2 1203612-68-3 1203612-69-4 1203612-70-7 1203612-71-8 1203612-72-9 1203612-73-0
RL: PRP (Properties)
(unclaimed protein sequence; ligand-binding domains derived from the two .alpha.-helical B domain of ***Staphylococcal*** protein A)

L13 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2009:1536815 CAPLUS <<LOGINID::20100301>>
DN 152:55952
TI Antibody combined with complement-depleting compound to enhance ADCC without inducing inflammation nor promoting tumor growth for cancer therapy
IN St. John, William D.; Weiner, George; Vogel, Carl-Wilhelm; Finnegan, Paul W.; Stark, Kevin L.; Fritzinger, David C.
PA Incode Biopharmaceutics, Inc., USA
SO PCT Int. Appl., 82pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009149306	A2	20091210	WO 2009-US46330	20090604
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2008-58777P	P	20080604		
	US 2008-104531P	P	20081010		
	US 2008-114939P	P	20081114		

AB Disclosed herein are methods and compns. for increasing the efficacy of monoclonal antibody therapies without inducing inflammation and/or agonizing the growth of a neoplastic cell. In some embodiments, the methods and compns. disclosed herein comprise co-administering an antibody and a complement modulating agent. The antibody is anti-CD20, -CD22,

-CD32b, -CD33, -CD40, -CD52, -EGFR, -VEGF, - ***HER2*** receptor, -17-1A, -CCR4, -IGF-1R, -CTLA-4 antibody or combination thereof. The complement-modulating compd. is GR-2II, AGIIa, AGIIb-1, AR-2IIa, AR-2IIb, AR-2IIc, CVF (cobra venom factor), human C3-CVF fusion protein, rC3, HC3-1496, HC3-1496-2, HC3-1496-3, HC3-1496-4, HC3-1496/1617, HC3-1496-8, HC3-1496-9, HC3-1496-10, HC3-1496-11, HC3-1496-12, HC3-1496-13, HC3-1496-14, HC3-1496-15, HC3-1496-16,HC3-1496-17, complement receptor 1, sCR1, APT070, TP10, TP20, etc.

AB . . . comprise co-administering an antibody and a complement modulating agent. The antibody is anti-CD20, -CD22, -CD32b, -CD33, -CD40, -CD52, -EGFR, -VEGF, - ***HER2*** receptor, -17-1A, -CCR4, -IGF-1R, -CTLA-4 antibody or combination thereof. The complement-modulating compd. is GR-2II, AGIIa, AGIIb-1, AR-2IIa, AR-2IIb, AR-2IIc, CVF. . .

IT Glycoproteins
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CVF (cobra venom factor), fragments and ***mutated*** derivs.; co-administration of therapeutic antibody and complement-depleting compd. to enhance ADCC without inducing inflammation nor promoting tumor growth for cancer therapy)

IT Proteins
RL: ARU (Analytical role, unclassified); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(Chemotaxis inhibitory; ***Staphylococcal*** ; co-administration of therapeutic antibody and complement-depleting compd. to enhance ADCC without inducing inflammation nor promoting tumor growth for cancer therapy)

IT Proteins
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ECB (extracellular complement binding) (***Staphylococcus*** aureus complement evasion mol.); co-administration of therapeutic antibody and complement-depleting compd. to enhance ADCC for cancer therapy)

IT ***Staphylococcus*** aureus
(chemotaxis inhibitory protein; co-administration of therapeutic antibody and complement-depleting compd. to enhance ADCC without inducing inflammation nor promoting tumor growth for cancer therapy)

IT 1200103-56-5D, Complement C3 (Human preproprotein), fragments and ***mutated*** derivs. 1200103-57-6D, fragments and ***mutated*** derivs.
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; co-administration of therapeutic antibody and complement-depleting compd. to enhance ADCC without inducing inflammation nor promoting tumor growth for cancer therapy)

IT 80295-41-6D, Complement C3, fragments and ***mutated*** derivs.
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human; co-administration of therapeutic antibody and complement-depleting compd. to enhance ADCC without inducing inflammation nor promoting tumor growth for cancer therapy)

L13 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2009:637603 CAPLUS <<LOGINID::20100301>>
TI Engineered Two-Helix Small Proteins for Molecular Recognition
AU Webster, Jack M.; Zhang, Rong; Gambhir, Sanjiv S.; Cheng, Zhen; Syud,

Faisal A.
CS Biosciences, Global Research, General Electric Company, Niskayuna, NY, 12309, USA
SO ChemBioChem (2009), 10(8), 1293-1296
CODEN: CBCHFX; ISSN: 1439-4227
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
AB Less is more: By starting with a high-affinity ***HER2*** -binding 3-helix affibody mol., we successfully developed 2-helix small protein binders with 5 nM affinities by using a combination of several different strategies. Our efforts clearly suggest that 2-helix small proteins against important tumor targets can be obtained by rational protein design and engineering.
OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
AB Less is more: By starting with a high-affinity ***HER2*** -binding 3-helix affibody mol., we successfully developed 2-helix small protein binders with 5 nM affinities by using a combination of several. . .
IT INDEXING IN PROGRESS
IT Biochips
Disulfide group
Epidermal growth factor receptors
Genetic engineering
Human
Immobilization, molecular or cellular
Molecular recognition
Mutation
Staphylococcal protein A
Surface plasmon resonance
(engineered two-helix small proteins for mol. recognition)

L13 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2008:1448250 CAPLUS <<LOGINID::20100301>>
DN 150:19087
TI Single-chain Fc (ScFc) regions, binding polypeptides comprising same, and methods related thereto
IN Farrington, Grahma K.; Saeed-Kothe, Amna; Garber, Ellen; Lugovskoy, Alexey Alexandrovich
PA Biogen Idec MA Inc., USA
SO PCT Int. Appl., 230 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008143954	A2	20081127	WO 2008-US6260	20080514
WO 2008143954	A3	20090319		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AU	2008254951	A1	20081127	AU 2008-254951	20080514
CA	2687117	A1	20081127	CA 2008-2687117	20080514
US	20090252729	A1	20091008	US 2008-152622	20080514
PRAI US	2007-930227P	P	20070514		
WO	2008-US6260	W	20080514		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention features polypeptides comprising an Fc region comprising genetically-fused Fc moieties. In addn., the invention provides methods for treating or preventing a disease or disorder in subject by administering the binding polypeptides to diseased subject.

IT Antibodies and Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(***Her2*** ; prepn. of single-chain Fc Igs for therapy in cancer, infection or inflammation)

IT Anti-infective agents
Anti-inflammatory agents
Anti-inflammatory agents
Antitumor agents
Antitumor agents
Autoimmune disease
Blood platelet
DNA sequences
Diagnosis
Disease, animal
Disulfide group
Disulfide group
Genetic vectors
Glycosylation
Human
Immunotherapy
Inflammation
Linking agents
Mutagenesis
Mutation
Neoplasm
Nervous system agents
Nervous system disease
Therapy
Transplant rejection
(prepn. of single-chain Fc Igs for therapy in cancer, infection or inflammation)

IT Complement
FcRn receptors
Gene, animal
Interleukin 1
Ligands
Peptides
Staphylococcal protein A
Streptococcal protein G
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(prepn. of single-chain Fc Igs for therapy in cancer, infection or inflammation)

L13 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2008:1435725 CAPLUS <<LOGINID::20100301>>
DN 150:50090
TI Effects of Lysine-Containing Mercaptoacetyl-Based Chelators on the Biodistribution of 99mTc-Labeled Anti- ***HER2*** Affibody Molecules
AU Tran, Thuy A.; Ekblad, Torun; Orlova, Anna; Sandstrom, Mattias; Feldwisch, Joachim; Wennborg, Anders; Abrahmsen, Lars; Tolmachev, Vladimir; Eriksson Karlstrom, Amelie
CS Unit of Biomedical Radiation Sciences, Rudbeck Laboratory Medical Radiation Physics, Uppsala University Hospital and Department of Medical Sciences, Uppsala University, Uppsala, Swed.
SO Bioconjugate Chemistry (2008), 19(12), 2568-2576
CODEN: BCCHES; ISSN: 1043-1802
PB American Chemical Society
DT Journal
LA English
AB The effects of polar (mercaptoacetyl-triseryl) and neg. charged (mercaptoacetyl-triglumatyl) chelators on the biodistribution of 99mTc-labeled anti- ***HER2*** Affibody mols. were previously investigated. With glycine, serine, and glutamate, we demonstrated that ***substitution*** with a single amino acid in the chelator can significantly influence the biodistribution properties and the excretion pathways. Here, we have taken this investigation further, by analyzing the effects of introduction of a pos. amino acid residue on the in vivo properties of the 99mTc-labeled Affibody mol. The Affibody mols. with mercaptoacetyl-seryl-lysyl-seryl (maSKS) and mercaptoacetyl-trilysyl (maKKK) extensions were produced by peptide synthesis and labeled with 99mTc in alk. conditions. A comparative biodistribution was performed in normal mice to evaluate the excretion pathway. A shift toward renal excretion was obtained when serine was ***substituted*** with lysine in the chelating sequence. The radioactivity in the gastrointestinal tract was reduced 3-fold for the 99mTc-maSKS-ZHER2:342 and 99mTc-maKKK-ZHER2:342 in comparison with the 99mTc-maSSS- ZHER2:342 conjugate 4 h post injection (p.i.). The radioactivity in the liver was elevated when a triple ***substitution*** of pos. charged lysine was used. The tumor targeting properties of 99mTc-maSKS-ZHER2:342 were further investigated in SKOV-3 xenografts. The tumor uptake of 99mTc-maSKS-ZHER2:342 was 17 .+. 7% IA/g 4 h p.i. Tumor xenografts were well-visualized by gamma scintigraphy. In conclusion, the ***substitution*** with one single lysine in the chelator results in better tumor imaging properties of the Affibody mol. ZHER2:342 and is favorable for imaging of tumors and metastases in the abdominal area. Multiple lysine residues in the chelator are, however, undesirable due to elevated uptake both in the liver and kidneys.
OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT
TI Effects of Lysine-Containing Mercaptoacetyl-Based Chelators on the Biodistribution of 99mTc-Labeled Anti- ***HER2*** Affibody Molecules
AB The effects of polar (mercaptoacetyl-triseryl) and neg. charged (mercaptoacetyl-triglumatyl) chelators on the biodistribution of 99mTc-labeled anti- ***HER2*** Affibody mols. were previously investigated. With glycine, serine, and glutamate, we demonstrated that ***substitution*** with a single amino acid in the chelator can significantly influence the biodistribution properties and the excretion pathways. Here, we. . . was performed in normal mice to evaluate the

excretion pathway. A shift toward renal excretion was obtained when serine was ***substituted*** with lysine in the chelating sequence. The radioactivity in the gastrointestinal tract was reduced 3-fold for the 99mTc-maSKS-ZHER2:342 and 99mTc-maKKK-ZHER2:342. . . with the 99mTc-maSSS- ZHER2:342 conjugate 4 h post injection (p.i.). The radioactivity in the liver was elevated when a triple ***substitution*** of pos. charged lysine was used. The tumor targeting properties of 99mTc-maSKS-ZHER2:342 were further investigated in SKOV-3 xenografts. The tumor. . . of 99mTc-maSKS-ZHER2:342 was 17 .+. 7% IA/g 4 h p.i. Tumor xenografts were well-visualized by gamma scintigraphy. In conclusion, the ***substitution*** with one single lysine in the chelator results in better tumor imaging properties of the Affibody mol. ZHER2:342 and is. . .

ST lysine mercaptoacetyl chelator technetium 99m ***HER2*** affibody pharmacokinetics

IT ***Staphylococcal*** protein A
RL: DGN (Diagnostic use); PKT (Pharmacokinetics); BIOL (Biological study); USES (Uses)
(Z-domain synthetic homologues; lysine-contg. mercaptoacetyl chelators effect on 99mTc-labeled anti- ***HER2*** affibody pharmacokinetics)

IT Chelating agents
Human
Pharmacokinetics
Scintigraphic agents
Scintigraphy
Structure-activity relationship
(lysine-contg. mercaptoacetyl chelators effect on 99mTc-labeled anti- ***HER2*** affibody pharmacokinetics)

IT neu (receptor)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lysine-contg. mercaptoacetyl chelators effect on 99mTc-labeled anti- ***HER2*** affibody pharmacokinetics)

IT Imaging
(tumor; lysine-contg. mercaptoacetyl chelators effect on 99mTc-labeled anti- ***HER2*** affibody pharmacokinetics)

IT 378784-45-3DP, Technetium 99m, chelator-anti- ***HER2*** affibody conjugate labeled with, biological studies 1056015-90-7DP, anti- ***HER2*** affibody conjugate, 99mTc labeled 1093184-00-9DP, anti- ***HER2*** affibody conjugate, 99mTc labeled 1093184-01-0DP, anti- ***HER2*** affibody conjugate, 99mTc labeled
RL: DGN (Diagnostic use); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(lysine-contg. mercaptoacetyl chelators effect on 99mTc-labeled anti- ***HER2*** affibody pharmacokinetics)

L13 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2008:702941 CAPLUS <<LOGINID::20100301>>
DN 149:47381
TI Two helix segment derived from ***Staphylococcal*** protein A domain B comprising a pair of anti-parallel alpha helixes capable of binding a target
IN Syud, Faisal Ahmed; Webster, Jack M.
PA General Electric Company, USA
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008070816	A2	20080612	WO 2007-US86708	20071207
	WO 2008070816	A3	20080918		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW		
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA		
	US 20080176278	A1	20080724	US 2006-608590	20061208
PRAI	US 2006-608590	A	20061208		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Provided herein are isolated polypeptides derived from the ***Staphylococcal*** protein A domain B comprising a pair of anti-parallel alpha helixes that are capable of binding a target. Also provided are nucleic acid sequences encoding such two helix binders, vectors contg. the nucleic acid sequences encoding for two helix binders, and host cells transformed with vectors contg. the nucleic acid sequences encoding for the two-helix binders. Also provided are methods of using the two helix binders. The polypeptides provided herein are derived from the Z-domain of protein A. The two helix binders provided herein demonstrate a binding affinity for the target in the range of about 50 pM to about 200 nM. The anti-IgG two helix binder described below in the Examples (SEQ ID NO.:7) has demonstrated an affinity of about 50 pM for its target, IgG. The anti- ***HER2*** two helix binder described in the Examples below (SEQ ID NO.:8) has demonstrated an affinity of about 150 nM for its target, ***HER2*** .

TI Two helix segment derived from ***Staphylococcal*** protein A domain B comprising a pair of anti-parallel alpha helixes capable of binding a target

AB Provided herein are isolated polypeptides derived from the ***Staphylococcal*** protein A domain B comprising a pair of anti-parallel alpha helixes that are capable of binding a target. Also provided. . . below in the Examples (SEQ ID NO.:7) has demonstrated an affinity of about 50 pM for its target, IgG. The anti- ***HER2*** two helix binder described in the Examples below (SEQ ID NO.:8) has demonstrated an affinity of about 150 nM for its target, ***HER2*** .

ST pair antiparallel alpha helix ***Staphylococcal*** protein A domain B

IT Antibodies and Immunoglobulins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (IgG, anti-parallel alpha helixes capable of binding; two helix segment derived from ***Staphylococcal*** protein A domain B comprising a pair of anti-parallel alpha helixes capable of binding a target)

IT neu (receptor)

RL: BSU (Biological study, unclassified); BIOL (Biological study) (anti-parallel alpha helixes capable of binding; two helix segment derived from ***Staphylococcal*** protein A domain B comprising a pair of anti-parallel alpha helixes capable of binding a target)

IT Diagnosis

(mol.; two helix segment derived from ***Staphylococcal*** protein A domain B comprising a pair of anti-parallel alpha helixes capable of binding a target)

IT Disulfide group
(two helix segment derived from Protein Z stabilized with; two helix segment derived from ***Staphylococcal*** protein A domain B comprising a pair of anti-parallel alpha helixes capable of binding a target)

IT Biomarkers
Protein sequences
.alpha.-Helix
(two helix segment derived from ***Staphylococcal*** protein A domain B comprising a pair of anti-parallel alpha helixes capable of binding a target)

IT ***Staphylococcal*** protein A
RL: BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); BIOL (Biological study); USES (Uses)
(two helix segment derived from ***Staphylococcal*** protein A domain B comprising a pair of anti-parallel alpha helixes capable of binding a target)

IT 1031901-13-9
RL: BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence, 35-residue; two helix segment derived from ***Staphylococcal*** protein A domain B comprising a pair of anti-parallel alpha helixes capable of binding a target)

IT 1031901-14-0
RL: BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence, SEQ ID NO: 2 and SEQ ID NO. 3 combined; two helix segment derived from ***Staphylococcal*** protein A domain B comprising a pair of anti-parallel alpha helixes capable of binding a target)

IT 1031467-43-2 1031467-44-3
RL: BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence, anti- ***Her2*** two helix binder with alternative ***substitutions*** with cysteine; two helix segment derived from ***Staphylococcal*** protein A domain B comprising a pair of anti-parallel alpha helixes capable of binding a target)

IT 1031467-42-1
RL: BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence, anti- ***Her2*** two helix binder with preferred ***substitutions*** with cysteine; two helix segment derived from ***Staphylococcal*** protein A domain B comprising a pair of anti-parallel alpha helixes capable of binding a target)

IT 1031467-41-0
RL: BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence, anti-IgG two helix binder with preferred ***substitutions*** with cysteine; two helix segment derived from ***Staphylococcal*** protein A domain B comprising a pair of anti-parallel alpha helixes capable of binding a target)

IT 1031901-16-2
RL: BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); BIOL (Biological study); USES (Uses)

(amino acid sequence, representative anti- ***Her2*** two helix binder; two helix segment derived from ***Staphylococcal*** protein A domain B comprising a pair of anti-parallel alpha helixes capable of binding a target)

IT 1031901-15-1
RL: BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence, representative anti-IgG two helix binder; two helix segment derived from ***Staphylococcal*** protein A domain B comprising a pair of anti-parallel alpha helixes capable of binding a target)

IT 1031468-61-7
RL: PRP (Properties)
(unclaimed protein sequence; two helix segment derived from ***Staphylococcal*** protein A domain B comprising a pair of anti-parallel alpha helixes capable of binding a target)

L13 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2007:1186922 CAPLUS <<LOGINID::20100301>>
DN 149:362696
TI 99mTc-chelator engineering to improve tumour targeting properties of a ***HER2*** -specific Affibody molecule
AU Engfeldt, Torun; Tran, Thuy; Orlova, Anna; Widstroem, Charles; Feldwisch, Joachim; Abrahmsen, Lars; Wennborg, Anders; Karlstroem, Amelie Eriksson; Tolmachev, Vladimir
CS School of Biotechnology, Royal Institute of Technology, Stockholm, Swed.
SO European Journal of Nuclear Medicine and Molecular Imaging (2007), 34(11), 1843-1853
CODEN: EJNMA6; ISSN: 1619-7070
PB Springer
DT Journal
LA English
AB Purpose Monitoring ***HER2*** expression is crucial for selection of breast cancer patients amenable to ***HER2*** -targeting therapy. The Affibody mol. ZHER2:342 binds to ***HER2*** with picomolar affinity and enables specific imaging of ***HER2*** expression. Previously, ZHER2:342 with the addnl. N-terminal mercaptoacetyl-glycyl-glycyl-glycyl (maGGG) sequence was labeled with 99mTc and demonstrated specific targeting of ***HER2*** -expressing xenografts. However, hepatobiliary excretion caused high radioactivity accumulation in the abdomen. We investigated whether the biodistribution of ZHER2:342 can be improved by ***substituting*** glycyl residues in the chelating sequence with more hydrophilic seryl residues. Methods The Affibody mol. ZHER2:342, carrying the chelators mercaptoacetyl-glycyl-seryl-glycyl (maGSG), mercaptoacetyl-glycyl-D-seryl-glycyl [maG(D-S)G] and mercaptoacetyl-seryl-seryl-seryl (maSSS), were prepd. by peptide synthesis and labeled with 99mTc. The differences in the excretion pathways were evaluated in normal mice. The tumor targeting capacity of 99mTc-maSSS-ZHER2:342 was studied in nude mice bearing SKOV-3 xenografts and compared with the capacity of radioiodinated ZHER2:342. Results A shift towards renal excretion was obtained when glycine was ***substituted*** with serine in the chelating sequence. The radioactivity in the gastrointestinal tract was reduced threefold for the maSSS conjugate in comparison with the maGGG conjugate 4 h post injection (p.i.). The tumor uptake of 99mTc-maSSS-ZHER2:342 was 11.5 .+. 0.5% IA/g 4 h p.i., and the tumor-to-blood ratio was 76. The pharmacokinetics and uptake characteristics of technetium-labeled ZHER2:342 were better than

those of radioiodinated ZHER2:342. Conclusion The introduction of serine residues in the chelator results in better tumor imaging properties of the Affibody mol. ZHER2:342 compared with glycyl-contg. chelators and is favorable for imaging of tumors and metastases in the abdominal area.

OSC.G 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI 99mTc-chelator engineering to improve tumour targeting properties of a ***HER2*** -specific Affibody molecule

AB Purpose Monitoring ***HER2*** expression is crucial for selection of breast cancer patients amenable to ***HER2*** -targeting therapy. The Affibody mol. ZHER2:342 binds to ***HER2*** with picomolar affinity and enables specific imaging of ***HER2*** expression. Previously, ZHER2:342 with the addnl. N-terminal mercaptoacetyl-glycyl-glycyl-glycyl (maGGG) sequence was labeled with 99mTc and demonstrated specific targeting of ***HER2*** -expressing xenografts. However, hepatobiliary excretion caused high radioactivity accumulation in the abdomen. We investigated whether the biodistribution of ZHER2:342 can be improved by ***substituting*** glycyl residues in the chelating sequence with more hydrophilic seryl residues. Methods The Affibody mol. ZHER2:342, carrying the chelators mercaptoacetyl-glycyl-seryl-glycyl. . . xenografts and compared with the capacity of radioiodinated ZHER2:342. Results A shift towards renal excretion was obtained when glycine was ***substituted*** with serine in the chelating sequence. The radioactivity in the gastrointestinal tract was reduced threefold for the maSSS conjugate in. . .

IT Animal cell line
(SKOV-3; 99mTc-chelator engineering to improve tumor targeting properties of ***HER2*** -specific Affibody mol.)

IT ***Staphylococcal*** protein A
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Z-domain synthetic homologues; 99mTc-chelator engineering to improve tumor targeting properties of ***HER2*** -specific Affibody mol.)

IT Drug delivery systems
(targeted; 99mTc-chelator engineering to improve tumor targeting properties of ***HER2*** -specific Affibody mol.)

IT Biological transport
(uptake; 99mTc-chelator engineering to improve tumor targeting properties of ***HER2*** -specific Affibody mol.)

IT Animal organ
Antitumor agents
Blood
Bone
Cecum
Chelating agents
Chirality
Human
Intestine
Kidney
Liver
Lung
Muscle
Neoplasm
Pharmacokinetics
Salivary gland
Spleen
Stability

Stomach
Thyroid gland
Urine
(99mTc-chelator engineering to improve tumor targeting properties of ***HER2*** -specific Affibody mol.)

IT neu (receptor)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(99mTc-chelator engineering to improve tumor targeting properties of ***HER2*** -specific Affibody mol.)

IT 14133-76-7, Technetium 99, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(Affibody chelator labeling by metastable; 99mTc-chelator engineering to improve tumor targeting properties of ***HER2*** -specific Affibody mol.)

IT 312-84-5, D-Serine
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(glycine ***substitution*** by; 99mTc-chelator engineering to improve tumor targeting properties of ***HER2*** -specific Affibody mol.)

IT 56-40-6, Glycine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(serine ***substitution*** of; 99mTc-chelator engineering to improve tumor targeting properties of ***HER2*** -specific Affibody mol.)

IT 66516-09-4
RL: PKT (Pharmacokinetics); BIOL (Biological study)
(99mTc-chelator engineering to improve tumor targeting properties of ***HER2*** -specific Affibody mol.)

IT 1056015-88-3DP, technetium 99m-labeled 1056015-89-4DP, technetium 99m-labeled 1056015-90-7DP, technetium 99m-labeled
RL: PKT (Pharmacokinetics); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(99mTc-chelator engineering to improve tumor targeting properties of ***HER2*** -specific Affibody mol.)

L13 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2005:582493 CAPLUS <<LOGINID::20100301>>
DN 143:103237
TI Synergistic adjuvants and antigens encapsulated into liposomes for prophylaxis and therapy
IN Konur, Abdo; Graser, Andreas
PA Vectron Therapeutics A.-G., Germany
SO Eur. Pat. Appl., 30 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1550458	A1	20050706	EP 2003-29801	20031223
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	AU 2004308642	A1	20050714	AU 2004-308642	20041222
	CA 2544893	A1	20050714	CA 2004-2544893	20041222
	WO 2005063288	A1	20050714	WO 2004-EP14630	20041222
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

EP 1711205 A1 20061018 EP 2004-804225 20041222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
JP 2007515451 T 20070614 JP 2006-546065 20041222
IN 2006DN02066 A 20070615 IN 2006-DN2066 20060417
US 20070298093 A1 20071227 US 2007-577800 20070124
PRAI EP 2003-29801 A 20031223
WO 2004-EP14630 W 20041222

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention relates to liposome, mixts. or liposomes and liposomal compns. comprising at least two different adjuvants and a therapeutic agent, their prodn. and use for the prevention and therapy of proliferative, infectious, vascular, rheumatoid, inflammatory, and immune diseases, in particular autoimmune diseases and allergies. Thus, antitumor effects of Pam3Cys and CpG-PTO ODNs as adjuvants were evaluated in mice inoculated with B16.F1 mouse melanoma cells. The tumor growth after immunization with low doses of antigenic peptide TRP-2 (SVYDFFVWL, 10 .mu.g per animal) encapsulated in AVE3 liposomes (cholesterol/DLPE/DOPS), with or without 2.5 mol% Pam3Cys as liposomal adjuvant, combined with low doses CpG-PTO ODNs (1.3 nmol) in saline or encapsulated into AVE3 was compared. The tumor mass was reduced when mice were immunized with TRP-2 antigen encapsulated in AVE3, with or without 2.5 mol% Pam3Cys plus encapsulated CpG-PTO ODNs 17 days after B16 inoculation, demonstrating that the encapsulation of the CpG-PTO is necessary to achieve a partial tumor rejection. In addn., the application of two encapsulated adjuvants, Pam3Cys and CpG-PTO ODN, further improved antitumor effects, which is in accordance with the synergistic effects obsd. ex vivo. No significant increase of the survival rate could be achieved with AVE3/TRP-2 plus CpG-PTO in saline. When mice were immunized with AVE3/Pam3Cys/TRP-2 plus CpG-PTO in saline the mean survival time significantly increased to 16 days. When mice were immunized with AVE3/TRP-2, with or without Pam3Cys, plus liposomal CpG-PTO, the mean survival time significantly increased to 19 days. In addn., these data showed that incorporation of Pam3Cys into antigen-carrying AVE3 only significantly increases the survival time when the vaccine setting includes unencapsulated CpG-PTO.

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT Antigens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(***HER2*** /neu; liposomes contg. antigens and synergistic adjuvants for vaccines for prevention and therapy of proliferative, infectious, vascular, inflammatory, and immune diseases)

IT Actinomyces
Actinomyces israelii
Adenoviridae

African swine fever virus
Arenaviridae
Bacillus (bacterium genus)
Bacillus anthracis
Bacteroides
Birnaviridae
Blastomyces
Blastomyces dermatitidis
Borrelia
Borrelia burgdorferi
Bunyaviridae
Caliciviridae
Campylobacter
Candida
Candida albicans
Chlamydia
Chlamydia trachomatis
Clostridium
Clostridium perfringens
Clostridium tetani
Coccidioides
Coccidioides immitis
Coronaviridae
Coronavirus
Corynebacterium
Corynebacterium diphtheriae
Cytomegalovirus
Dengue virus
Ebola virus
Enterobacter
Enterobacter aerogenes
Enterococcus
Enterococcus faecalis
Enterovirus
Equine encephalosis virus
Erysipelothrix
Erysipelothrix rhusiopathiae
Escherichia
Filoviridae
Flaviviridae
Fusobacterium
Fusobacterium nucleatum
Haemophilus
Haemophilus influenzae
Hantaan virus
Helicobacter
Helicobacter pylori
Hepadnaviridae
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
Herpesviridae
Herpesviridae
Histoplasma
Histoplasma capsulatum
Human coxsackievirus
Human echovirus

Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human immunodeficiency virus 1
Human parainfluenza virus
Human poliovirus
Influenza virus
Iridoviridae
Klebsiella
Klebsiella pneumoniae
Legionella
Legionella pneumophila
Leptospira
Leptospira interrogans
Listeria
Listeria monocytogenes
Marburg virus
Measles virus
Mumps virus
Mycobacterium
Mycobacterium avium
Mycobacterium gordonae
Mycobacterium intracellulare
Mycobacterium kansasii
Mycobacterium tuberculosis
Nairovirus
Neisseria
Neisseria gonorrhoeae
Neisseria meningitidis
Orbivirus
Orthomyxoviridae
Papillomavirus
Papovaviridae
Paramyxoviridae
Parvoviridae
Parvovirus
Pasteurella
Pasteurella multocida
Phlebovirus
Picornaviridae
Polyomavirus
Porphyromonas
Porphyromonas gingivalis
Poxviridae
Poxviridae
Rabies virus
Reoviridae
Respiratory syncytial virus
Retroviridae
Rhabdoviridae
Rhinovirus
Rotavirus
Rubella virus
Simian virus 40
Staphylococcus
Staphylococcus aureus
Streptobacillus

Streptobacillus moniliformis
Streptococcus
Streptococcus agalactiae
Streptococcus bovis
Streptococcus pneumoniae
Streptococcus pyogenes
Togaviridae
Treponema
Treponema maltophilum
Treponema pallidum pertenue
Trypanosoma cruzi
Vaccinia virus
Variola virus
Yellow fever virus
(antigens; liposomes contg. antigens and synergistic adjuvants for vaccines for prevention and therapy of proliferative, infectious, vascular, inflammatory, and immune diseases)

IT Ras proteins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(p21ras, ***mutations*** ; liposomes contg. antigens and synergistic adjuvants for vaccines for prevention and therapy of proliferative, infectious, vascular, inflammatory, and immune diseases)

L13 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2005:34770 CAPLUS <<LOGINID::20100301>>
DN 142:109117
TI Her-2 receptor-binding derivatives of ***Staphylococcal*** protein A for use in diagnosis and therapy of cancer
IN Carlsson, Joergen; Stahl, Stefan; Eriksson, Tove; Gunneriusson, Elin; Nilsson, Fredrik
PA Affibody AB, Swed.
SO PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005003156	A1	20050113	WO 2004-SE1049	20040630
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004253835	A1	20050113	AU 2004-253835	20040630
AU 2004253835	B2	20090129		
CA 2531238	A1	20050113	CA 2004-2531238	20040630
EP 1641818	A1	20060405	EP 2004-749087	20040630
EP 1641818	B1	20081203		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

	CN 1816563	A	20060809	CN 2004-80019059	20040630
	JP 2007537700	T	20071227	JP 2006-518586	20040630
	AT 416190	T	20081215	AT 2004-749087	20040630
	ES 2319426	T3	20090507	ES 2004-749087	20040630
	IN 2005KN02544	A	20061013	IN 2005-KN2544	20051209
	US 20100048868	A1	20100225	US 2006-563310	20060512
PRAI	SE 2003-1987	A	20030704		
	SE 2004-275	A	20040209		
	WO 2004-SE1049	W	20040630		

AB ***Substitution*** derivs. of the Z domain of ***Staphylococcal*** protein A (SPA) with a strong, specific, binding affinity for ***HER2*** are described for use in the diagnosis and treatment of ***her2*** -dependent cancers. A gene for the protein and l expression vectors and host cells for manuf. of the protein are also described. Also provided is the use of such a polypeptide as a medicament, and as a targeting agent for directing substances conjugated thereto to cells overexpressing ***HER2*** . The specificity of binding of the protein for the receptor allows its use in drug targeting with minimal side effects. Methods, and kits for performing the methods, are also provided, which methods and kits rely on the binding of the polypeptide to ***HER2*** . The proteins were identified in combinatorial libraries by panning. The protein manufd. in Escherichia coli bound to ***HER2*** -bearing SKBR-3 cells. The protein was well-tolerated by injection when given to nude mice bearing SKOV-3 cell implants. The protein was accumulated rapidly in SKOV-3 cells.

OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Her-2 receptor-binding derivatives of ***Staphylococcal*** protein A for use in diagnosis and therapy of cancer

AB ***Substitution*** derivs. of the Z domain of ***Staphylococcal*** protein A (SPA) with a strong, specific, binding affinity for ***HER2*** are described for use in the diagnosis and treatment of ***her2*** -dependent cancers. A gene for the protein and l expression vectors and host cells for manuf. of the protein are also. . . of such a polypeptide as a medicament, and as a targeting agent for directing substances conjugated thereto to cells overexpressing ***HER2*** . The specificity of binding of the protein for the receptor allows its use in drug targeting with minimal side effects.. . . kits for performing the methods, are also provided, which methods and kits rely on the binding of the polypeptide to ***HER2*** . The proteins were identified in combinatorial libraries by panning. The protein manufd. in Escherichia coli bound to ***HER2*** -bearing SKBR-3 cells. The protein was well-tolerated by injection when given to nude mice bearing SKOV-3 cell implants. The protein was. . .

ST ***HER2*** binding ***Staphylococcus*** protein cancer diagnosis therapy

IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(A, Her-2 receptor-binding derivs.; her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)

IT Enzymes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ADEPT, conjugates with her-2-binding proteins; her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and

therapy of cancer)

IT Proteins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(G, fusion products, with protein A derivs., serum albumin and her-2 receptor binding by; her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)

IT Chemotherapy
(antibody-directed enzyme, enzymes of, conjugates with her-2-binding proteins; her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(c-myc, epitopes, fusion proteins with protein A derivs.; her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)

IT Human
(cancer diagnosis and therapy; her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)

IT Diagnosis
(cancer, detection of her-2 receptor in; her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)

IT Antitumor agents
Radioactive substances
(conjugates with her-2-binding proteins; her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)

IT Cytokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates with her-2-binding proteins; her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)

IT Toxins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cytotoxins, conjugates with her-2-binding proteins; her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)

IT Blood plasma
Body fluid
(detection of her-2 receptor in; her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)

IT Drug delivery systems
Test kits
(her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)

IT neu (receptor)
RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)

IT Neoplasm
(her-2-dependent, treatment of; her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)

IT Diagnosis
(mol., of cancer, detection of her-2 receptor in; her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)
IT Dissociation constant
(of her-2 receptor and protein A derivs.; her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)
IT Protein sequences
(of protein A variants of ***Staphylococcus*** ; her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)
IT Protein engineering
(of protein binding by ***Staphylococcal*** protein A; her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)
IT Blood-coagulation factors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(precursors, conjugates with her-2-binding proteins; her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)
IT Albumins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(serum, protein A derivs. binding ***her2*** receptors and; her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)
IT ***Mutation***
(***substitution*** , effects on protein binding by ***Staphylococcal*** protein A; her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)
IT 823575-28-6 823575-29-7 823575-30-0 823575-31-1 823575-32-2
823575-33-3 823575-34-4 823575-35-5 823575-36-6 823575-37-7
823575-38-8 823575-39-9 823575-40-2 823575-41-3 823575-42-4
823575-43-5 823575-44-6 823575-45-7 823575-46-8 823575-47-9
823575-48-0 823575-49-1 823575-50-4 823575-51-5 823575-52-6
823575-53-7 823575-54-8 823575-55-9 823575-56-0 823575-57-1
823575-58-2 823575-59-3 823575-60-6 823575-61-7 823575-62-8
823575-63-9 823575-64-0 823575-65-1 823575-66-2 823575-67-3
823575-68-4 823575-69-5 823575-70-8 823575-71-9 823575-72-0
823575-73-1 823575-74-2 823575-75-3 823575-76-4 823575-77-5
823575-78-6 823575-79-7 823575-80-0 823575-81-1 823575-82-2
823575-83-3 823575-84-4 823575-85-5 823575-86-6 823575-87-7
823575-88-8 823575-89-9 823575-90-2 823575-91-3 823575-92-4
823575-93-5 823575-94-6 823575-95-7 823575-96-8 823575-97-9
823575-98-0 823575-99-1 823576-00-7 823576-01-8 823576-02-9
823576-03-0 823576-04-1 823576-05-2
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; her-2 receptor-binding derivs. of ***Staphylococcal*** protein for use in diagnosis and therapy of cancer)
IT 64134-30-1DP, Hexahistidine, fusion proteins with protein A derivs.
98849-88-8DP, FLAG (peptide), fusion proteins with protein A derivs.
RL: BPN (Biosynthetic preparation); BUU (Biological use, unclassified); BIOL (Biological study); PREP (Preparation); USES (Uses)
(her-2 receptor-binding derivs. of ***Staphylococcal*** protein for

use in diagnosis and therapy of cancer)
IT 823578-05-8 823578-06-9
RL: PRP (Properties)
(unclaimed sequence; her-2 receptor-binding derivs. of ***Staphylococcal*** protein A for use in diagnosis and therapy of cancer)

L13 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
AN 1992:405736 CAPLUS <<LOGINID::20100301>>
DN 117:5736
OREF 117:1195a,1198a
TI Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments
AU Kelley, Robert F.; O'Connell, Mark P.; Carter, Paul; Presta, Leonard; Eigenbrot, Charles; Covarrubias, Michael; Snedecor, Brad; Bourell, James H.; Vetterlein, David
CS Dep. Protein Eng., Genentech, Inc., South San Francisco, CA, 94080, USA
SO Biochemistry (1992), 31(24), 5434-41
CODEN: BICHAW; ISSN: 0006-2960
DT Journal
LA English
AB The murine monoclonal antibody 4D5 (anti-p185HER2) inhibits the proliferation of human tumor cells overexpressing p185HER2 in vitro and has been humanized (Carter, et al., 1991) for use in human cancer therapy. The antigen binding thermodn. and the antiproliferative activities were detd. of chimeric 4D5 Fab (ch4D5 Fab) fragment and a series of 8 humanized Fab (hu4D5 Fab) fragments differing by amino acid ***substitutions*** in the framework regions of the variable domains. Fab fragments were expressed by secretion from Escherichia coli and purified from fermn. supernatants by using affinity chromatog. on immobilized streptococcal protein G or ***staphylococcal*** protein A for ch4D5 and hu4D5, resp. CD spectroscopy indicates correct folding of the E. coli produced Fab, and scanning calorimetry shows a greater stability for hu4D5, (Tm = 82.degree.) as compared with ch4D5 Fab (Tm = 72.degree.). KD Values for binding to the extracellular domain (ECD) of p185HER2 were detd. by using a RIA; the .DELTA.H and .DELTA.Cp for binding were detd. by using isothermal titrn. calorimetry. Ch4D5 Fab and one of the humanized variants (hu4D5-8 Fab) bind p185HER2-ECD with comparable affinity (.DELTA.G.degree. = -1.36 kcal mol-1). The enthalpy changes assocd. with binding, however, are considerably different (ch4D5 Fab .DELTA.H = -17.2 .+. 1.5 kcal mol-1; hu4D5-8 Fab .DELTA.H = -12.9 .+. 0.4 kcal mol-1), which suggests a significant difference in the mechanism of antigen binding. This difference may be important for antiproliferative activity since ch4D5 Fab retains activity whereas hu4D5-8 Fab is inactive. Thus, KD measurements alone are insufficient in an attempt to reproduce the activity of a murine antibody in a humanized form. Anal. of the thermodn. data using an empirical method (Sturtevant, J. M., 1977) indicates that differences in the hydrophobic or vibrational contributions to binding cannot account for equiv. .DELTA.G but can account for differing .DELTA.H. The hydrophobic contribution to antigen binding is equiv. for ch4D5 and hu4D5-8 Fab and is consistent with burial of about 960 .ANG.2 of nonpolar surface area upon complex formation.
OSC.G 45 THERE ARE 45 CAPLUS RECORDS THAT CITE THIS RECORD (45 CITINGS)
AB . . . chimeric 4D5 Fab (ch4D5 Fab) fragment and a series of 8 humanized Fab (hu4D5 Fab) fragments differing by amino acid ***substitutions*** in the framework regions of the variable domains. Fab fragments were expressed by secretion from Escherichia coli and purified from fermn.

supernatants by using affinity chromatog. on immobilized streptococcal protein G or ***staphylococcal*** protein A for ch4D5 and hu4D5, resp. CD spectroscopy indicates correct folding of the E. coli produced Fab, and scanning. . .

ST chimeric antibody p185 ***HER2*** Fab antitumor; antigen binding antibody p185HER2 Fab fragment